The Role of H19, a Long Non-coding RNA, in Liver Development by Pope, Chad
University of Connecticut
OpenCommons@UConn
Doctoral Dissertations University of Connecticut Graduate School
7-31-2017
The Role of H19, a Long Non-coding RNA, in
Liver Development
Chad Pope
chad.pope@uconn.edu
Follow this and additional works at: https://opencommons.uconn.edu/dissertations
Recommended Citation
Pope, Chad, "The Role of H19, a Long Non-coding RNA, in Liver Development" (2017). Doctoral Dissertations. 1588.
https://opencommons.uconn.edu/dissertations/1588
i 
 
The Role of H19, a Long Non-coding RNA, in Liver Development 
 
 
Chad Alan Pope, Ph.D. 
University of Connecticut, 2017 
 
Liver development at the postnatal age has been understudied despite being a time when 
the liver is rapidly growing and changing its primary function as an organ involved in 
hematopoiesis to an organ responsible for metabolism.  Long non-coding RNAs (LncRNAs) are 
important in many biological processes, including organogenesis, normal liver functions, and 
liver diseases.  Expression levels of lncRNAs change in identifiable patterns in liver during 
development, and H19, due to its expression pattern, may be important for liver development. 
H19 RNA is highly expressed at early postnatal ages and precipitously decreases at a 
specific time corresponding with increases in expression of genes important for mature liver 
function, such as drug metabolizing enzymes.  H19’s role in the regulation of liver maturation is 
currently unknown.  Using an H19 knockout mouse model to determine the role of H19 in liver 
development, we quantified gene expression for insulin growth factor signaling, Wnt signaling, 
key cytochrome P450 (P450) enzymes known to change as the liver develops, and fetal and adult 
plasma protein produced in liver.  In mice lacking H19 expression, liver weights were 
significantly increased immediately after birth and significant increases were found in the 
number of actively proliferating cells.  Increases in cell proliferation may be due to increases in 
β-catenin protein affecting Wnt signaling, increases in insulin-like growth factor 2 (IGF2) 
expression, and/or increases in insulin-like growth factor 1 receptor (IGF1R) expression at the 
protein level.  Loss of targeted inhibition of IGF1R by microRNA 675 (miR-675) may be the 
cause of IGF1R increases, as miR-675 expression is also abrogated with loss of H19 expression  
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in our model.  P450 expression patterns were significantly altered for certain P450 genes at 
particular time points in development, but were largely unchanged.  No change in the production 
of plasma proteins was found, indicating H19 may not be important for liver maturation despite 
its role in controlling cell proliferation during liver growth.  H19 may be important for normal 
liver development, and understanding how the liver matures will assist in predicting drug 
efficacy and toxicity in pediatric populations.   
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Chapter 1: Introduction/Literature Review 
1.1 Liver Development 
Liver development requires specific temporal molecular events leading to the generation 
of each specific cell type, and the formation of a precise three-dimensional architecture.  In 
mammals, the liver forms one cell thick cords of polarized hepatocytes.  Hepatocytes secrete 
hormones into the blood from their basolateral surface, and they secrete bile acids and bile salts 
across their apical surface into tight junctions that form canaliculus surrounding each hepatocyte 
(Si-Tayeb et al., 2010).  The liver lobes are distinctively arranged containing one centrilobular 
vein at the lobe center and the portal triad consisting of the hepatic artery, portal vein, and one or 
two bile ducts (Mescher and Junqueira, 2013).  The hepatic artery supplies blood from the heart 
and the portal vein supplies blood from the gastrointestinal tract, gallbladder, pancreas, and 
spleen.  Blood leaves the liver to return to the heart via the centrilobular vein.  The axis between 
the portal triad and the centrilobular vein separates liver cells into distinct zones.  Zone 1 
contains oxygen rich cells near the portal triad, zone 3 contains cells near the centrilobular vein, 
and zone 2 is comprised of cells in-between.  Cell function and gene expression exhibit different 
patterns depending on zonal location.  For example, the metabolism of xenobiotics mainly occurs 
in hepatocytes closer to the centrilobular vein in zone 2 and zone 3 while gluconeogenesis occurs 
more in the periportal region in zone 1.  Canonical Wnt signaling plays a key role in maintaining 
hepatocyte zonation in mice (Monga and SpringerLink (Online service), 2011). 
 Liver ontogenesis is complex and tightly orchestrated.  Hepatocytes and biliary epithelial 
cells are formed from the endoderm germ layer in the embryo.  Stromal cells, stellate cells, 
Kuppfer cells, and blood vessels are derived from the mesoderm.  In mice, the endoderm forms 
around embryonic days 6.5 to 7.5 and by embryonic day 15, hepatoblasts are formed which will 
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eventually differentiate into hepatocytes and biliary cells (Zorn, 2008).  Prior to hepatoblast 
formation, the endoderm cells near the sinus venosus become columnar and begin to express 
genes indicating hepatic cell fate at embryonic day 8.5 (Bort et al., 2006).  The initiation of liver 
ontogeny is when epithelial cells of the foregut endoderm commit to becoming the liver 
primordium at around embryonic day nine (Hata et al., 2007).  And, after embryonic day 9.5, the 
matrix on the basal surface of the endoderm near the sinus venosus degrades, and hepatoblast 
cords migrate into the surrounding stroma (Bort et al., 2006).  Between embryonic days 10 to 15 
the liver becomes the major hematopoietic organ in the fetus (Zorn, 2008) and throughout 
ontogenesis until it is fully mature, gene expression profiles change in identifiable patterns (Li et 
al., 2009a).  
Wnt signaling plays important roles in proper fetal liver organogenesis.  Acting to repress 
Hhex in the posterior endoderm during early somite stages, Wnt signaling prevents ectopic 
hepatic development.  Repression of Wnt signaling allows Hhex expression in the anterior 
endoderm, allowing liver formation.  After hepatic specification, Wnt signaling acts in the 
opposite manner to promote hepatogenesis (McLin et al., 2007).  In rats, Wnt2 increases 
proliferation of sinusoidal endothelial cells by targeting VEGF receptor-2 (Klein et al., 2008), 
and activation of the VEGF receptor in mice results in sinusoidal endothelial cell secretion of 
mitogenic factors increasing hepatocyte proliferation and liver mass (LeCouter et al., 2003).  
Wnt signaling also promotes stem cell specification to cholangiocytes in embryonic mouse liver 
cultured ex vivo (Hussain et al., 2004).  Before birth, this pathway clearly acts to instruct liver 
development, and after birth, as the liver continues to grow and mature, Wnt signaling remains a 
key factor. 
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Wnt signaling is important for postnatal liver growth and maturation.  ß-Catenin has been 
shown to be critical for early postnatal liver growth, as knockout results in a reduction in cell 
proliferation (Apte et al., 2007).  Aside from growth, Wnt signaling impacts normal liver 
functions including affecting expression of drug metabolizing enzymes and influencing bile acid 
homeostasis.  For example, ß-catenin activates P450s (Loeppen et al., 2005), and knockout of ß-
catenin results in lower expression of P450s (Sekine et al., 2006).  ß-Catenin knockout mice 
exhibit a decrease in bile flow and mild intrahepatic cholestasis with an inability to respond to 
increases in bile acids (Yeh et al., 2010).  Acting before and after birth, Wnt signaling directs 
proper liver growth and maturation. 
Insulin-like growth factor (IGF) signaling is important for proper development.  IGF 
signaling is due to two ligands, IGF1 and IGF2, capable of activating receptors, IGF1R and 
IGF2R.  IGF1R responds to both ligands, while IGF2R only responds to IGF2.  Growth hormone 
from the pituitary stimulates the liver to release IGF, and binding to the tyrosine kinase receptor, 
IGF1R, results in receptor autophoshorylation activating phosphorylation of various intracellular 
substrates.  Positive signaling requires IGF binding to IGF1R, but IGF2 binding to IGF2R serves 
to limit IGF2 to dampen positive signaling (Baker et al., 1993).  Most tissue in human and mouse 
express IGF1R and respond to each isoform of IGF, which are dominantly expressed at different 
stages of liver development.  Human and mouse livers express IGF2 early in life, and levels 
decline as the liver matures.  IGF1 exhibits the opposite expression, and is not highly expressed 
until the liver is fully mature.  Therefore, IGF2 has been described as a fetal growth factor while 
IGF1 is considered an adult growth factor.  Mouse knockout studies have elucidated the 
influence of IGF1, IGF2, and IGF1R on total body weight indicating IGF signaling is important 
for normal growth.  Disruption of either IGF1 or IGF2 in mice results in a reduction in total body 
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weight to 60% of normal weight at embryonic day 18.5.  Disruption of IGF1R expression has an 
even more dramatic impact on total body weight.  Mice embryonic day 18.5 are only 40% 
normal wild type weight (Baker et al., 1993). 
Hematopoiesis occurs in site specific locations depending on the stage of development.  
Prior to liver formation, hematopoiesis occurs in the aorta-gonad-mesonephros region in the 
embryonic mesoderm.  Here, oncostatin M acts to stimulate development of both hematopoietic 
cells and endothelial cells.  After the liver begins to form, it accepts hematopoietic stem cells and 
begins to function to support the production (erythropoiesis) and decomposition of red blood 
cells.  Fetal liver is the major hematopoietic organ in the body before birth.  Hematopoietic cells 
of the liver produce oncostatin M, and this promotes liver maturation through differentiation 
(Miyajima et al., 2000).  After the liver gains maturity, the differentiated cells are no longer able 
to support hematopoiesis, and the formation of blood stem cells shifts from being produced in 
liver to being produced in bone marrow.  However, after this switch, the liver continues to be 
important for blood functions producing plasma proteins including albumin, the most abundant 
protein in blood serum, and coagulation factors.  Liver also filters the blood and metabolizes 
various compounds included unneeded hormones and harmful chemicals. 
 A major function of the liver is to metabolize endogenous and exogenous compounds to 
be cleared by the body so they do not accumulate and reach potentially toxic levels.  Exogenous 
compounds such as xenobiotics are metabolized by P450s, and expression of specific P450s 
depends on the maturity of the liver.  Certain isoforms of different P450s are expressed before 
life and early life while other forms are present only in fully mature adult liver.  For example, in 
mice, CYP3A11 is not highly expressed before or immediately following birth.  CYP3A11 
gradually increases in expression as the liver matures.  Opposite to this, CYP3A16 is only highly 
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expressed in fetal and early postnatal livers of mice (Peng et al., 2012).  Similarly in human, the 
major CYP3A isoform is CYP3A4 in the adult liver, but during early liver development, 
CYP3A7 is the dominate CYP3A isoform (Lacroix et al., 1997).  The major CYP3A isoform 
expressed depends on the stage of development of the liver.  CYP2C29 and CYP2B10 are 
important xenobiotic metabolizing P450s that also exhibit a distinct pattern of expression during 
liver development.  CYP2C29 is not highly expressed until the adult ages, while CYP2B10 
expression is at its highest during the postnatal adolescent stage (Peng et al., 2012).  Comparing 
the normal pattern of expression of well-characterized P450s to experimental conditions can 
allow for the determination of proper liver development.  
 Another function of liver is production of serum proteins which bind cations, fatty acids, 
and bilirubin.  Two serum proteins, albumin and α-fetoprotein are produced at different levels 
during liver maturation, and comparing their patterns of expression in experimental conditions 
may allow examination of changes in proper liver development.  In human, α-fetoprotein serum 
levels are high only in the embryo and fetus and drop to low levels after birth.  Human albumin 
serum levels rise from low expression in the fetus to high expression in adult, but are always 
expressed at a higher level than α-fetoprotein even in early development (Nayak and Mital, 
1977).  Albumin functions as the main protein in blood to regulate oncotic pressure, however, the 
function of α-fetoprotein is less clear, despite being heavily expressed in fetal liver.   
1.2 Long Non-Coding RNA in Liver Development 
Long non-coding RNA (LncRNA) are transcripts greater than 200 nucleotides that do not 
code for protein.  Despite not being translated, approximately 35,000 lncRNAs have been 
discovered as of 2005.  LncRNAs exhibit characteristics of mRNA such as being 5’ capped, 
spliced, and poly-adenylated (Carninci et al., 2005).  LncRNAs are also generated similarly to 
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proteins having similar histone-modification profiles, splicing signals, and exon and intron 
lengths (Derrien et al., 2012).  LncRNAs are highly abundant comprising 80% of all 
transcription (Kapranov et al., 2007), and their expression levels are highly tissue specific 
(Derrien et al., 2012) indicating their potential importance in regulating cell differentiation. 
Many lncRNAs have been discovered as being regulators of gene expression.  For 
example, HOTAIR binds to histone modification complexes including Polycomb Repressive 
Complex 2 (PRC2) capable of repressing transcription of the HOXD locus through epigenetic 
modification (Tsai et al., 2010).  And XIST, one of the first characterized lncRNAs capable of 
manipulating gene expression, inactivates an X-chromosome in female placental mammals 
controlling gene dosage between XY males and XX females by first accumulating on the 
chromosome followed by recruitment of PRC1 and PRC2 leading to epigenetic gene silencing 
(Wutz and Gribnau, 2007).  LncRNAs have also been implicated in more broad biologically 
relevant functions including controlling cell lineages by maintenance of stem cell quiescence 
(Venkatraman et al., 2013), pluripotency (Fatica and Bozzoni, 2014), and differentiation (Fatica 
and Bozzoni, 2014).  This section highlights liver lncRNAs and their importance in normal 
development, normal liver functions, and in disease states as well as describes the various 
molecular mechanisms liver lncRNAs use to achieve their biological function. 
LncRNAs are important regulators of normal liver development.  LncRNAs are 
differentially expressed throughout different stages of development, and our laboratory has 
previously characterized, using whole transcriptome analysis, the expression of liver lncRNAs 
by RNA-sequencing in mice before birth to adult (Peng et al., 2014).  We have discovered that 
there are three major oncogenic patterns of differential expression that occur at the neonatal, 
adolescent, and adult stages indicating differential lncRNA expression highlighting their 
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important role in growth and development.  Another lab has done similar work to characterize 
mouse liver transcriptomes during development.  They examined mouse livers at embryonic days 
14.5 and 18 as well as adult livers, and have found similar results indicating that lncRNA 
expression is temporal and exists in patterns throughout development (Lv et al., 2014).  For 
example, as the liver ages, changes in transcription of lncRNAs occurs.  In mice, it was 
discovered lncRNAs MEG3, RIAN, and MIRG all increased in mice aged 28 months compared 
to young adults, four months old (White et al., 2015).  Differences in lncRNA expression is not 
limited to different developmental stages.  Many liver lncRNAs are differentially expressed due 
to growth hormone regulation.  This results in sex-biased expression of lncRNAs (Melia et al., 
2015).  Liver lncRNAs may be important in regulating different developmental programs in liver 
due to having precise timing in their expression at particular stages during development. 
1.3 Long Non-Coding RNA in Liver Functions  
1.3.1 LncRNAs in Hematopoiesis 
LncRNAs have been shown to play important roles in hematopoiesis.  Erythropoiesis is 
regulated by the survival of red blood cell lineage-committed precursors and lincRNA-EPS has 
been shown to inhibit the apoptosis of red blood cell precursors in fetal liver (Paralkar and 
Weiss, 2011).  There is a balance between the inhibition and promotion of apoptosis in this 
lineage.  Erythropoietin, the major erythropoietic cytokine, binds the Epo receptor initiating 
signaling pathways that inhibit apoptosis of erythroid precursors (Paralkar and Weiss, 2011), 
while signal transduction through Fas and tumor necrosis factor receptors promotes apoptosis.  
LincRNA-EPS was shown to promote erythropoiesis through the prevention of apoptosis of red 
blood cell precursors by potentially binding Pycard to inhibit its transcription by recruiting 
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transcriptional repressor complexes (Paralkar and Weiss, 2011).  PYCARD normally activates 
caspases to induce apoptosis, but is inactive leading to lineage progression.   
MALAT1 is another lncRNA that controls lineage progression in hematopoiesis.  
MALAT1 expression is high in early-stage progenitor cells, and low in late-stage progenitor 
cells.  Knockdown of MALAT1 inhibits erythroid myeloid lymphoid cell (a mouse multipotent 
hematopoietic cell line) proliferation after the tumor suppressor, p53, binds to the Malat1 
promoter to repress its transcription (Ma et al., 2015).  MALAT1 is also a good example of a 
lncRNA having multiple functions.  MALAT1 plays roles in liver regeneration (Li et al., 2017), 
glucose homeostasis, liver fibrosis (Yu et al., 2015a), HCC, and can be used as a predictive 
biomarker for disease in humans (Konishi et al., 2015).  LncRNAs controlling differentiation 
have been widely reported in literature for various cell types and organs, including the liver.  
1.3.2 LncRNAs in Lipid Metabolism and Homeostasis 
Metabolism of endogenous compounds is also an important function of liver, and there 
have been many studies examining the roles of lncRNAs in lipid metabolism and lipid 
homeostasis with a focus on disease states regarding lipid metabolism disorder.  Fatty acids, 
including the most common non-toxic form, triacylglycerols, are the most commonly stored and 
circulating forms of energy.  The liver is the hub of fatty acids synthesis, lipogenesis, and lipid 
circulation (Nguyen et al., 2008).  Improper lipid homeostasis can result in diseases, including 
metabolic syndromes such as obesity and type 2 diabetes.  
LncLSTR has been shown to be a regulator of triglycerides by interacting with TDP-43, a 
transcriptional suppressor of CYP8B1 expression.  This interaction leads to increased CYP8B1 
activity, resulting in changes in bile acid ratios which induce apolipoprotein C2 expression 
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through FXR.  Increased apolipoprotein C2 leads to lipoprotein lipase activation and increased 
plasma triglyceride clearance (Li et al., 2015b). 
Lnc-HC regulates cholesterol metabolism by forming a complex with hnRNPA2B1 (Lan 
et al., 2015).  This protein-RNA complex then binds to CYP7A1 and ABCA1 mRNA inhibiting 
their expression.  CYP7A1 and ABCA1 are implicated in cellular cholesterol excretion, so when 
the level of lnc-HC is increased, a risk for cholesterol disorder is also increased.  Furthermore, 
high cholesterol upregulates lnc-HC expression through the activator C/EBPß (Lan et al., 2015). 
1.3.3 LncRNAs in Liver Regeneration 
 Aside from normal hepatic growth during development, the liver also has the ability to 
grow after injury after either physical (surgical removal) or chemical (hepatotoxicity) insult 
(Michalopoulos and DeFrances, 1997).  This is a remarkable ability owing to being the only 
visceral organ capable of regeneration and needing only as little as 33% normal tissue for re-
growth to its original mass with minimal disturbance in liver functions such as glucose 
regulation, blood protein synthesis, bile synthesis, and drug metabolism (Michalopoulos and 
DeFrances, 1997). 
Activation of the cell cycle is needed for liver regeneration.  To replace injured tissue, the 
organ needs to participate in massive cell-division.  Two lncRNAs have been proven to be 
important in this process both using the same mechanism to activate the cell cycle.  LncRNA-
LALR1 (Xu et al., 2013) and MALAT1 (Li et al., 2017) enhance cell proliferation during liver 
regeneration by activation of Wnt/ß-catenin signaling facilitating the expression of cyclin D1 
through suppression of Axin1.  Mechanistically, lncRNA-LALR1 suppresses expression of 
Axin1 by recruiting CTCF to its promoter (Xu et al., 2013).  
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1.4 Long Non-Coding RNA in Liver Diseases 
1.4.1 LncRNAs in Glucose Homeostasis 
Glucose homeostasis is an important function of liver and is influenced by lncRNA 
regulation.  Many lncRNAs have been implicated in controlling glucose homeostasis (Sun and 
Wong, 2016).  In particular, the previously discussed MALAT1 also appears to influence the 
pathogenesis of diabetes.  MALAT1 is upregulated in diabetic rat and mice models and 
participates in crosstalk with the p38 MAPK signaling pathway regulating endothelial cell 
function (Liu et al., 2014).  Another multifunctional lncRNA, MEG3, is most often studied for its 
role in cancer (Anwar et al., 2012; Zhuo et al., 2016), but has been shown to enhance insulin 
resistance in type 2 diabetes (Zhu et al., 2016).  MEG3 increases FOXO1 expression, and 
FOXO1 is associated with characteristics of type 2 diabetes including hyperglycemia and 
hypertriglyceridemia.  MEG3 is a well-studied lncRNA also having been studied in multiple 
liver diseases and disorders including fibrosis (He et al., 2014). 
1.4.2 LncRNAs in Liver Fibrosis, Fatty Liver Diseases 
Many lncRNAs work in tandem to regulate liver fibrosis.  For example, lincRNA-p21 
inhibits the activation, proliferation, and cell cycle progression of stellate cells to reduce fibrosis 
and is decreased in patients with fibrosis and cirrhosis (Zheng et al., 2015), and MALAT1 is 
upregulated in liver fibrosis acting as a competing endogenous RNA for miR-101b which 
normally represses RAC1 leading to an increase in stellate cell proliferation, activation, and 
progression of the cell cycle (Yu et al., 2015a). 
H19 was recently implicated in being important in bile acid homeostasis.  Bile is 
produced in liver and functions to aid digestion of lipids by emulsification in the small intestine.  
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Cholestatic liver fibrosis can occur after small heterodimer partner (SHP) degradation by BCL2, 
an antiapoptotic regulator protein.  SHP normally acts to transcriptionally repress H19, and H19 
is not found in normal healthy adult liver.  If H19 not repressed, liver injury, fibrosis, and 
inflammation occurs alongside an increase in serum bile acids and bilirubin (Zhang et al., 2016).   
Another lncRNA, HULC, is upregulated in HCC and promotes lipogenesis to increase 
triglyceride and cholesterol levels in cancer cells.  HULC activates PPARA by inhibiting 
expression of miR-9, an inhibitory microRNA against PPARA mRNA.  PPAR activates the 
ACSL1 promoter when not inhibited due to HULC coordinating methylation of the miR-9 
promoter.  ACSL1 generates cholesterol which further promotes HULC’s ability through 
positive feedback (Cui et al., 2015). 
Specific lncRNAs implicated in liver fibrosis have been shown to affect the profibrogenic 
factor TGF-β1 (Yang et al., 2015; Yu et al., 2015b).  APTR is increased in the stellate cells of 
fibrotic liver, and APTR promotes upregulation of α-smooth muscle actin in stellate cells 
through TGF-β1 signaling (Yu et al., 2015b).  TGF-β1 signaling also downregulates MEG3 to 
promote liver fibrosis.  A downregulation of MEG3 is achieved by promoter methylation (Yang 
et al., 2015). 
LncRNA GAS5 inhibits the activation of stellate cells and is another regulator of liver 
fibrogenesis.  miR-222 targets GAS5 and inhibits its expression, and reciprocally, GAS5 binds 
miR-222 to reduce its expression.  Both reduction of miR-222 and GAS5 occur at the RNA level.  
Therefore, due to competition, higher levels of GAS5 results in greater inhibition of miR-22 
expression.  As a result of the reduction of miR-222 by GAS5, p27 increases, because miR-222 
also binds competitively to inhibit this protein.  An increase in p27 results in inhibition of the 
activation and proliferation of stellate cells (Yu et al., 2015c). 
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Berberine, a compound isolated from Chinese herbal medicines, reduces hepatic steatosis 
through lncRNAs to ameliorate Non-Alcoholic Fatty Liver Disease (NAFLD).  Steatotic liver 
has reduced levels of both lncRNA MRAK052686 and Nrf2, but these levels recover with 
berberine treatment.  Interestingly, berberine was found to change the expression profiles of 538 
lncRNAs in steatotic livers of mice (Yuan et al., 2015). 
1.4.3 LncRNAs in Liver Injury 
Hematopoietic stem cell transplantation after radiation and chemotherapy can cause 
damage to hepatocytes and sinusoidal endothelial cells leading to hepatic veno-occlusive disease, 
and lncRNAs have been shown to be affected.  LncRNAs were found to be dysregulated in 
hepatocytes (2,918 upregulated and 1,911 downregulated) after hematopoietic stem cell 
transplantation, and pathway analysis revealed increased T-cell receptor signaling and a decrease 
in VEGF signaling (Qiao et al., 2016). 
Injury to liver tissue after liver is harvested and placed in cold storage prior to 
transplantation is an important concern.  TUG1 has been found to be decreased during cold 
storage, and overexpression of TUG1 in mouse livers has been found to decrease injury after 
cold storage by preventing mitochondrial apoptosis and inhibiting endoplasmic reticulum stress 
pathways in hepatocytes and sinusoidal endothelial cells leading to increased graft survival (Su 
et al., 2016a). 
1.4.4 LncRNAs in HBV and HCV Infection 
LncRNAs also have consequences in liver diseases caused by viral infection.  Both 
hepatitis B virus (HBV) and hepatitis C virus (HCV) have the potential to change cellular 
regulatory mechanisms that lead to hepatocellular carcinoma (HCC).  HBV and HCV can impact 
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chromosomal instability and alter gene expression.  HCV, an RNA virus, affects liver and acute 
and chronic symptoms resemble HBV symptoms.  In contrast to HBV, HCV infection tends to 
lead to chronic infection.  There is no approved vaccine for HCV, but recently drug treatment has 
been shown to cure the disease with a greater than 95% effective rate (Hoofnagle and Sherker, 
2014).  In HCV related HCC, lncRNA expression profiles are altered including upregulation of 
LINC01419 and AK021443, while lncRNA AF070632 is downregulated (Zhang et al., 2015b).  
In HBV, hepatitis B virus X protein (HBx) is a well cited transactivating viral protein capable of 
dysregulating many liver cell functions including cell cycle progression and apoptosis leading to 
HCC.  Infection with HBV, a DNA virus, can result in a few weeks of acute symptoms including 
vomiting, yellowish skin, tiredness, dark urine, and abdominal pain.  Chronic HBV may result in 
cirrhosis and liver cancer with death in 15 to 25% of patients.  Since 1982, infection by HBV has 
been preventable by vaccination (Pungpapong et al., 2007).  LncRNA-Dreh may be important in 
HBV related liver diseases as it is downregulated by HBx.  LncRNA-Dreh was found to be a 
tumor suppressor inhibiting tumor growth and metastasis in HCC caused by HBV.  
Mechanistically, LncRNA-Dreh was able to repress vimentin by binding the protein which 
results in inhibition of tumor metastasis (Huang et al., 2013).   
LncRNA HOTAIR and PLK1 kinase are also increased in HBV-induced liver 
carcinogenesis.  HOTAIR binds both the repressive factors SUZ12 and ZNF198 to enhance 
PLK1 ubiquitination and subsequent protesomal degradation of SUZ12 and ZNF198.  Their 
downregulation leads to epigenetic reprogramming in HBx-expressing cells, notably the 
modification of the EPCAM promoter, a gene important for cell adhesion and transformation 
(Zhang et al., 2015a). 
1.4.5 LncRNAs in Progression of Hepatocellular Carcinoma 
14 
 
HCC is the most studied liver disease, and there have been many newly discovered roles 
that various lncRNAs play in its progression.  HCC is the fifth most common cancer (Parkin et 
al., 2005) and the most common liver cancer accounting for 75% of all primary cases (Ahmed 
and Lobo, 2009).  HCC has many known risk factors, including HBV and HCV (Tanaka et al., 
2011).  Treatment includes liver transplantation with a survival rate ranging from 67% to 91% 
from studies performed in the late 2000’s (Vitale et al., 2007), pharmacological intervention with 
a tyrosine kinase inhibitor, sorafenib, that inhibits tumor-cell proliferation (Llovet et al., 2008), 
or surgical resection (Ang et al., 2015). 
LncRNA research in liver diseases has focused on HCC and many lncRNAs have been 
discovered that are important for disease initiation and progression.  Many studies utilize 
transcriptome and sequencing analysis to discover lncRNAs that are upregulated or 
downregulated at the transcriptome level in HCC compared to normal tissue (Esposti et al., 
2016).  Other studies examine variations in lncRNA copy number at the DNA level (Zhou et al., 
2015).  From there, the identified differentially expressed lncRNAs are studied further to 
determine their exact roles in disease often discovering one or more clear molecular mechanism 
for their actions.  General characterization studies use tools that indicate regulation pathways 
where lncRNAs participate.  For example, one particular study finds a total of 5,525 lncRNAs in 
23 liver tissue samples comprised of controls, cirrhosis, and HCC and finds 57 differentially 
regulated lncRNAs that participate in cell cycle regulation, TGF-β signaling, and liver 
metabolism (Esposti et al., 2016).  Alternatively, examination of lncRNAs expressed in fetal 
liver compared to adult can point to potential oncofetal genes.  Often lncRNAs that are 
ectopically expressed in adult tissue indicates dysregulation and increased cell proliferation as 
seen in cancer or liver regeneration after injury.  Many lncRNAs have been discovered to be 
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important in liver cancer by this method including lncRNA PVT1 (Wang et al., 2014) and H19 
(Ariel et al., 1998).  
An example of an HCC liver lncRNA discovered using genome sequencing is lncRNA-
PRAL.  Variations in the copy number of this gene were discovered.  Deletion of lncRNA-PRAL, 
a lncRNA that induces apoptosis through p53 regulation, has been associated with a decrease in 
HCC survival.  In mice where tumors have been induced, delivery of lncRNA-PRAL reduces 
tumor volume (Zhou et al., 2015).  To highlight the various mechanisms lncRNAs can achieve, 
we focus here on the molecular mechanisms involved in HCC with emphasis on the similarities 
and differences of their molecular functions. 
1.4.6 Molecular Mechanisms of LncRNA in Hepatocellular Carcinoma 
Recent studies have suggested that initiation of HCC beings with progenitor cells of the 
liver rather than the parenchyma.  The lncRNA CUDR accelerates liver cancer stem cell growth 
by binding cyclin D1 and as a complex, binding both the promoters of H19 and c-myc.  Increased 
expression of H19 promotes excessive TERT enhancing telomerase activity and c-myc increases 
liver cancer stem cell proliferation (Pu et al., 2015).  CUDR also interacts with another lncRNA, 
HULC, in tumorigenesis (Gui et al., 2015).  CUDR enhances embryonic stem cell differentiation 
using epigenetic modifying mechanisms.  It was shown to inhibit histone H3K27 trimethylation 
and to decrease promoter methylation of HULC.  CUDR is also capable of changing chromatin 
looping promoting recruitment of RNA polymerase II and P300 via CTCF.  HULC is also 
implicated in promoting angiogenesis by upregulating SPHK1 through sequestering miR-107 
which normally targets and inhibits the transcription factor E2F1 (Lu et al., 2016b).  LncRNA 
DILC represses self-renewal and expansion of liver cancer stem cells and has been found to be 
decreased in HCC.  DILC binds the IL6 promoter to inhibit its transcription leading to decreased 
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STAT3 activation (Wang et al., 2016c).  LINC00152 activates the mTOR pathway and binds the 
EPCAM promoter to potentially promote cell proliferation (Ji et al., 2015).  H19 has been widely 
implicated as being important in HCC.  H19 knockdown in cancer cell lines, such as Hep3B, has 
been shown to decrease tumor weight and tumor volume (Matouk et al., 2007).  A microRNA 
that is transcribed within the first exon of H19 has been shown to upregulate H19 expression in 
HCC.  miR675 inhibits HP1α causing histone modifications in the EGR1 promoter (reduced 
H3K9 trimethylation, reduced H3K27 trimethylation, and increased H3K27 acetylation) 
enhancing its transcription.  EGR1 upregulates H19 which activates PKM2 promoting 
tumorigenesis (Li et al., 2015a). 
Previously mentioned lncRNA PVT1 is increased in HCC and indicates poor prognosis.  
PVT1 binding to NOP2 is needed for this lncRNA to increase cell proliferation, cell cycling 
genes, and generate a more stem-cell like property of cells.  Stabilization and upregulation of 
NOP2 is also stabilized by this binding (Wang et al., 2014). 
Epigenetic modifying enzymes impart histone modifications or chemically alter DNA 
itself, such as simply adding methylation, influence the accessibility of the transcriptional 
machinery towards particular genes therefore influencing gene expression.  Guide lncRNAs act 
by bringing epigenetic modifying enzymes to impact transcription.  A clear example of a guide 
lncRNA is lncRNA-HEIH.  LncRNA-HEIH binds the enhancer EZH2, a component of PRC2, 
the histone remodeling complex capable of repressing target genes through methylation of 
H3K27 (Yang et al., 2011).  LncRNA-HEIH essentially guides the repressive complex to genes 
targeted by EZH2.  Another example of a guide lncRNA is HOTTIP.  However, HOTTIP 
interacts instead with a transcriptional activating complex, WDR5/MLL, that promotes HOXA 
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genes through H3K trimethylation (Quagliata et al., 2014) showing that liver lncRNAs can act as 
both positive and negative regulators of gene expression. 
Many liver lncRNAs function as decoys limiting expression of proteins by binding and 
sequestering them.  For example, lncRNA-Dreh is capable of altering the filament and 
cytoskeleton structure of cells by binding vimentin, an intermediate filament protein, to inhibit 
its expression (Huang et al., 2013).  Similarly, lncRNA-MVIH associates with PGK1, a 
glycolytic enzyme, to disallow its function in angiogenesis (Yuan et al., 2012).  In converse, the 
binding of proteins to lncRNAs can also serve to enhance expression of that protein such as the 
scaffold/guide lncRNA-PRAL.  LncRNA-PRAL binds HSP90 and p53 promoting HSP90-p53 
interaction which stabilizes p53 by disallowing MDM2 binding and ubiquitination of p53 (Zhou 
et al., 2015).  These mechanisms are also examples of lncRNAs that do not directly bind DNA to 
regulate transcription, but rather affect the availability or stability, affecting transcriptional 
regulation or simple positive or negative expression of that particular molecule. 
LncRNAs can also be destabilized to limit their function as in the case of lncRNA 
HULC.  IGF2BP1 binds and destabilizes lncRNA HULC through the recruitment of CNOT1 
protein, the scaffold of the CCR4-NOT deadenylase complex, which is important for the 
cytoplasmic RNA decay machinery (Hammerle et al., 2013).  In this example, the lncRNA is not 
the decoy, but rather the protein is the decoy titrating away the lncRNA limiting its biological 
function to impact gene regulation. 
LncRNAs in liver have complex regulation schemes.  LncRNA-ATB is regulated by 
TGF- ß and then lncRNA-ATB itself regulates multiple signaling processes.  Acting as a decoy, 
in this case against miRNA instead of protein, lncRNA-ATB titrates away the miR-200 family 
(Sun and Wong, 2015).  miR-200s act to repress the epithelial-mesenchymal transition (EMT) 
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inducing transcription factors, ZEB1 and ZEB2, at the mRNA level.  LncRNA-ATB also 
regulates the IL-11/STAT3 pathway by stabilizing IL-11 mRNA leading to increased IL-11 
protein secretion (Sun and Wong, 2015).  
In the previous examples of miRNA regulation, liver lncRNAs require physical binding 
to miRNAs serving as decoys titrating away these repressors from being biologically active.  
However, lncRNAs can also regulate miRNA by other mechanisms.  LncRNA DANCR blocks 
miRNA repression by binding CTNNB1 mRNA which is normally repressed by miR-214, miR-
320, and miR-199a (Yuan et al., 2016).  Here, the lncRNA serves not as a decoy but rather a 
shield for repression similarly like lncRNA-PRAL that blocks ubiquitination stabilizing p53.  In 
this example, however, the mRNA and not the protein is protected. 
1.4.7 LncRNAs as Biomarkers 
Early indication of disease can lead to quicker diagnosis and treatment preceding better 
health outcomes due to the prevention of irreversible precipitous disease progression.  
Misdiagnosis is also an obstacle in healthcare, because often clinical treatment itself causes death 
and disease.  For example, globally it has been estimated that 141,700 people died in 2013 from 
the effects of medical treatment (Mortality and Causes of Death, 2015) indicating a need for 
correct diagnosis preventing unneeded treatments.  Finding ways to diagnose that are non-
invasive are also more practical, usually more cost-effective, and less harmful to patients.  
Therefore, correct, quick, and noninvasive diagnosis is an important health concern, and 
biomarkers have become a more widely used useful tool. 
Finding new biomarkers indicating disease using body fluids that are easily obtained as 
opposed to other methods, such as tissue biopsy, which are invasive and impractical in many 
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circumstances, can potentially lead to better and faster diagnosis.  Many lncRNAs have been 
found in blood that could potentially serve as indicators of disease.  For example, APTR is 
elevated in serum of patients with liver cirrhosis and research has proposed its role as being 
potential marker for the disease (Yu et al., 2015b). 
Biomarkers for HCC are also in demand due to the need for early diagnosis of cancer for 
better survival potential.  Many lncRNAs have been proposed for this purpose.  Not only is 
MALAT1 expression higher in solid tumors, but elevated levels in the plasma is associated with 
liver damage and can predict development of HCC (Konishi et al., 2015).  Linc00974 is stably 
expressed in plasma, and using qRT-PCR combination analysis for both linc00974 and 
CYFRA21-1, an already established tumor marker, high prediction of oncogenesis, tumor 
growth, and metastasis in HCC patients could be achieved (Tang et al., 2014).  Linc00974 
upregulates KRT19 by acting as a competitive endogenous RNA for KRT19’s inhibitor miR-
642.  Increasing KRT19 expression activates Notch and TGF-β signaling. 
Other lncRNAs have potential for being serum biomarkers, but have yet been tested for 
this purpose.  High expression of lnc-DILC predicts early recurrence and short survival of 
patients with HCC indicating it may have prognostic value (Wang et al., 2016c), however it has 
yet to be tested for its prediction of disease after isolation from blood.  Further research that 
discovers positive correlation to lncRNAs in blood with early disease need exploration to aid in 
early and correct diagnosis for rapid disease treatment. 
The contents of extracellular vesicles is gaining new attention emerging as potential 
biomarkers for disease.  Extracellular vesicles are present in many biological fluids including 
blood, urine, and bile (Patel, 2014).  To be effective biomarkers, the contents of extracellular 
vesicles needs to reflect the contents of the cell of origin, be different between healthy and 
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disease, and be reliably detected (Mohankumar and Patel, 2015).  Characterization of lncRNAs 
differentially expressed in diseased patients from isolated extracellular vesicles has found 
promising results.  Three potential lncRNA biomarkers, RP11-160H22.5, XLOC_014172, and 
LOC149086, were recently found to be upregulated in extracellular vesicles found in plasma of 
patients diagnosed with HCC (Tang et al., 2015).  And, lincRNA-ROR, which is also packaged 
in extracellular vesicles, has the potential to indicate drug sensitivity to chemotherapy against 
HCC (Takahashi et al., 2014).  Linc-ROR is increased in HCC chemoresistance.  With sorafenib 
treatment, linc-ROR increases in both cells and extracellular vesicles excreted by tumor cells.  
When linc-ROR is increased, there is lower apoptosis and cytotoxicity with drug treatment.  
Mechanistically, TGF-β enriches linc-ROR within extracellular vesicles (Takahashi et al., 2014). 
1.4.8 Targeting lncRNAs 
Novel drug targets to treat disease and biomarkers to correctly and quickly diagnose 
disease have the potential to greatly impact human health.  New targets will allow for more 
effective therapies and reduce the need for drugs with harmful side effects.  Due to lncRNAs 
being highly tissue specific (Derrien et al., 2012), using them as drug targets has the potential to 
reduce off-target effects and limit unwanted, harmful side effects.  The liver is an essential organ.  
It serves vital functions that are indispensable from the beginning of life before birth to 
adulthood.  Its necessity is emphasized by its capability to regenerate after injury.  Research 
discovering the biological functions of lncRNAs is becoming more and more prevalent as their 
functions have been found to be more and more abundant and diverse.  As more lncRNAs are 
discovered to be important in normal growth and in diseased states, more targets for therapies 
and biomarkers will be generated.  Deeply understanding the mechanisms that lncRNA utilize to 
regulate gene function and various other processes will not only give us insights in how our body 
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normally functions but also how disease progresses.  As technology and innovation advances, the 
discovery of new lncRNAs and how they impact the liver will continue and yield fascinating 
insights into basic liver physiology and help to better treat liver disease. 
1.5. Targeting H19, an Imprinted Long Non-Coding RNA, in Hepatic Functions and Liver 
Diseases 
1.5.1 Abstract 
H19 is a long non-coding RNA regulated by genomic imprinting through methylation at 
the locus between H19 and IGF2.  H19 is important in normal liver development, controlling 
proliferation and impacting genes involved in an important network controlling fetal 
development.  H19 also plays a major role in disease progression, particularly in hepatocellular 
carcinoma.  H19 participates in the epigenetic regulation of many processes impacting diseases, 
such as activating the miR-200 pathway by histone acetylation to inhibit the epithelial-
mesenchymal transition to suppress tumor metastasis.  Furthermore, H19’s normal regulation is 
disturbed in diseases, such as hepatocellular carcinoma.  In this disease, aberrant epigenetic 
maintenance results in biallelic expression of IGF2, leading to uncontrolled cellular proliferation.  
This section aims to aid further research utilizing H19 for drug discovery and the treatment of 
liver diseases by focusing on both the epigenetic regulation of H19 and how H19 regulates 
normal liver functions and diseases, particularly by epigenetic mechanisms. 
1.5.2 Introduction 
H19, a long non-coding RNA (lncRNA), is both epigenetically regulated and utilizes 
epigenetic mechanisms to regulate liver cell functions.  We will first describe the history of H19 
and then focus on the regulation of the gene expression of H19.  It is uniquely expressed from 
22 
 
one allele by an intricate process called genomic imprinting.  Then, we will examine H19’s roles 
and implications in various normal functions in liver development and growth, including the 
regulation of bile acid homeostasis and xenobiotic metabolism.  We will discuss dysregulation of 
H19 in the progression of liver-related diseases, including steatosis, fibrosis, cirrhosis, diabetes, 
and hepatocellular carcinoma (HCC) with a particular focus on the epithelial to mesenchymal 
transition (EMT).  Finally, we will explore using H19 in therapies for liver diseases either by 
targeting H19 or by directly using the H19 promoter to drive selective toxicity in cancer.  The 
mechanisms of regulation will be highlighted, emphasizing epigenetic mechanisms. 
The discovery and characterization of H19, one of the first lncRNAs described, 
overviews how lncRNAs were first discovered and assumed to have functions despite not coding 
for protein.  In 1984, the Tilghman lab discovered an RNA transcript that was highly expressed 
in fetal mouse liver, but decreased in adult liver.  They screened a fetal liver cDNA library for 
moderately abundant clones that hybridized only to a fetal liver cDNA probe, but did not 
hybridize to an adult liver cDNA probe and other controls; the clone was designated H19 based 
on its position being the 19th clone in row H.  In the discussion of their paper, Pachnis et al. 
state, “The identity of this protein encoded by H19, if indeed one exists, is unknown at this time” 
(Pachnis et al., 1984).  Further characterization by sequencing revealed that H19 had multiple 
translation termination signals in all three reading frames, but conversely, was highly conserved.  
H19 was still transcribed by RNA polymerase II, spliced, and polyadenylated, but puzzlingly did 
not associate with ribosomes.  This dual nature of being similar to protein-coding genes, but 
incapable of translation led the authors to conclude “…the product of this unusual gene may be 
an RNA molecule“ (Brannan et al., 1990).  Since then, genome-wide technologies, such as 
microarrays, particularly tiling arrays, which allow for characterization of sequenced regions 
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where function was not known, resulted in a boom of lncRNA discovery.  Technology continues 
to develop at an alarming rate, and the fascinating H19 discovery was only the beginning of a 
new field in science. 
There are numerous reviews discussing the vast amount of research on H19.  Prior 
reviews cover topics as extensive as H19’s regulation (Sasaki et al., 2000; Banerjee et al., 2001; 
Gabory et al., 2006; Nordin et al., 2014), or its broad role in cancer (Raveh et al., 2015; Jing et 
al., 2016; Matouk et al., 2016).  Other reviews are more specific to particular types of cancer 
(Wake et al., 1998; Matouk et al., 2015; Lin et al., 2016).  There is a need for more reviews 
discussing diseases in a particular organ, especially the liver.  When H19 is discussed in the 
context of HCC, reviews examine other lncRNAs in their analysis without focus on H19.  First, 
will be a description of H19’s role in liver diseases, including HCC, with a particular emphasis in 
any epigenetic regulation where H19 participates.  We will also highlight research from other 
organ systems that need translational examination in the liver.  Overall, we aim to provide a 
resource for future research on H19, so liver diseases may be treated more effectively in the 
future. 
1.5.3 Characterization of H19 and Its Participation in Epigenetic Regulation 
1.5.3.1. LncRNAs 
LncRNAs are transcripts greater than 200 nucleotides that do not code for proteins.  
Despite not being translated, approximately 35,000 lncRNAs have been discovered that exhibit 
characteristics of mRNA, such as being 5′ capped, spliced, and poly-adenylated (Carninci et al., 
2005).  Furthermore, lncRNAs are generated similarly to proteins, having similar histone-
modification profiles, splicing signals, and exon and intron lengths (Derrien et al., 2012).  
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LncRNAs are abundant, comprising 80% of all transcripts (Kapranov et al., 2007) and their 
expression levels are highly tissue specific (Derrien et al., 2012). 
Molecular functions of lncRNAs are described as signals, decoys, guides, and scaffolds 
(Wang and Chang, 2011). LncRNAs act effectively as signals due to their specific expression in 
specific cell types and stages of development as well as their capability to respond to stimuli.  
Many lncRNAs found in liver currently described in the literature can be classified as signals due 
to being tissue specific, disease state specific, and/or developmentally specifically expressed.  
LncRNAs also act as decoys by binding and titrating away proteins.  They can be guides capable 
of binding regulatory molecules, including chromatin remodelers and transcription factors, 
directing them to specific DNA targets to control gene expression.  With different domains 
capable of binding different molecules, they can also be scaffolds, assembling a complex 
arrangement of components (Wang and Chang, 2011). Thus, lncRNAs can exhibit many 
functions and work within the cell to regulate different processes by various molecular 
mechanisms. 
1.5.3.2 H19 
The characteristics of H19 are similar to other lncRNAs in both structure and their 
temporal and tissue-specific expression pattern.  Structurally, the H19 gene contains five exons 
and four introns, producing a 2.3-kb lncRNA after splicing.  The H19 gene contains shorter 
introns than most lncRNA genes, each less than 100 base pairs (Kent et al., 2002). It is 
transcribed from chromosome 7 in the mouse and chromosome 11 in the human.  It is adjacent to 
the protein-coding gene, insulin-like growth factor 2 (IGF2), an important fetal growth factor.  
These two genes share regulatory sequences required for their expression, including two 
enhancers located 3’ downstream of H19 (Leighton et al., 1995b).  Their expression is also 
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controlled by an imprinting control region (ICR) between the two gene loci and exhibits 
differential methylation (Drewell et al., 2002).  Temporally, H19 is expressed in the embryo, but 
subsequently downregulated in all tissues, excluding skeletal muscle, shortly after birth 
(Brunkow and Tilghman, 1991). During the fetal and postnatal ages, H19 is abundant in the 
liver.  H19 expression has been shown to correlate with the expression of IGF2, implicating 
H19’s important role in liver development. 
H19 has many diverse biological functions.  It is known to participate in the regulation of 
cell proliferation (Yamamoto et al., 2004) and differentiation (Dey et al., 2014), as well as its 
role in cancer both as an oncogene (Hibi et al., 1996; Barsyte-Lovejoy et al., 2006) and as a 
tumor suppressor (Yoshimizu et al., 2008). In the developing fetus, H19 regulates a number of 
important genes within the imprinted gene network (IGN), including Igf2, responsible for proper 
embryonic development (Gabory et al., 2010). Due to participating in many known biological 
functions and being one of the first lncRNAs discovered and characterized, H19 is one of the 
most well-studied lncRNAs. 
The H19 locus harbors multiple transcripts (Figure 1.1).  The main transcript, H19, 
functions as the full lncRNA, and it encodes within its first exon two variants of microRNA, 
miR-675 (Dey et al., 2014). There are also two antisense transcripts produced from the locus, 
91H and HOTS.  The HOTS transcript can produce a nucleolar protein (Onyango and Feinberg, 
2011), while 91H appears to function solely as an lncRNA (Berteaux et al., 2008).  A review and 
discussion on the antisense transcripts is presented in Section 1.5.7.  
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Figure 1.1  Transcription at the H19 locus consists of the well-characterized H19 lncRNA (A) 
and its microRNA miR-675 (B) encoded within the first exon of H19.  Two antisense transcripts 
are also formed from the locus.  91H RNA (C) is described as varying in length, but can 
potentially be transcribed from the complementary DNA strand entirely encompassing H19 and 
other portions of its regulatory sequences.  HOTS RNA (D) is transcribed from most of the 
antisense sequence of H19 and upstream bases.  HOTS can be translated to form a nucleolar 
protein. 
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1.5.3.3 Regulation of H19 Expression by Epigenetic Mechanisms 
H19 is regulated by the epigenetic phenomenon, genomic imprinting.  Normally, H19 is 
only expressed from one parental allele and silenced epigenetically on the reciprocal 
chromosome.  The paternal allele is imprinted, or silenced, due to the highly methylated ICR 
found between H19 and IGF2.  The ICR is a differentially methylated region (DMR) due to 
having different methylation statuses depending on the chromosomal parental origin.  At the 
maternal allele, H19 is expressed, and on this chromosome, the ICR is hypomethylated 
(Manoharan et al., 2004).  IGF2 is also imprinted, but opposite of H19, expression is driven from 
the paternal allele and the maternal allele is silenced (DeChiara et al., 1991). The same ICR also 
controls IGF2 imprinting.  Located approximately 2 kb upstream of the H19 promoter between 
H19 and IGF2, this region regulates monoallelic expression of those genes by being 
differentially methylated depending on the parental origin of the allele.  In normal conditions, the 
ICR is hypermethylated at the paternal allele and hypomethylated at the maternal allele.  This 
balance is important in controlling normal expression of these genes.  Deleting 10 kb upstream 
H19 disrupts this region and causes biallelic IGF2 expression, thereby disrupting imprinting 
(Ripoche et al., 1997).  The mechanism controlling imprinting of H19 and IGF2 involves the 
binding of either MeCP2 or CTCF based on the methylation status of the ICR. 
On the hypermethylated ICR found on the paternal chromosome, H19 is repressed and 
IGF2 expressed.  H19 expression is silenced through histone deacetylation by MeCP2 binding to 
methylated CpG dinucleotides.  After binding, histone deacetylases (HDACs) interact with 
MeCP2 to repress H19 (Drewell et al., 2002).  Furthermore, in this state of ICR methylation, the 
ICR binds another DMR located within IGF2, DMR2.  This ICR and DMR2 interaction moves 
IGF2 into position to interact with the enhancer region driving IGF2 expression (Kurukuti et al., 
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2006).  The binding of the insulator CTCF to the ICR is disallowed due to the high number of 
methyl groups (Kurukuti et al., 2006). 
Conversely, on the hypomethylated ICR found on the maternal chromosome, H19 
expression is not repressed by MeCP2 binding and able to interact with its enhancer region.  
CTCF is allowed to bind, insulating and preventing the expression of IGF2 by two known 
mechanisms.  First, CTCF binding allows the interaction of the ICR with matrix attachment 
region 3 (MAR3) and another DMR, DMR1, which is located in an intergenic region of IGF2.  
These interactions result in a loop around IGF2 and impediment of expression (Kurukuti et al., 
2006), as well as disallowing the enhancers from interacting with IGF2 (Murrell et al., 2004). 
Specifically in liver, the binding of CTCF to the ICR is mediated by the interaction of CTCF 
with prohibitin 1 (Ramani et al., 2016). Second, CTCF interacts with the IGF2 promoter region 
and recruits polycomb repressive complexes leading to H3K27 methylation causing suppression 
of IGF2 (Li et al., 2008). 
In summary, two states on separate parental alleles exist in normal conditions when H19 
and IGF2 are co-expressed.  On the paternal allele, the ICR is methylated, and the enhancer 
region is able to interact with IGF2 to allow expression.  On the maternal allele, the ICR is not 
methylated, allowing the same enhancer region to, instead, drive H19 expression.  Therefore, this 
region and its methylation status are critical for both H19 and IGF2 expression, expressed 
coordinately albeit from opposite alleles. 
1.5.3.4 H19 Regulates Gene Expression by Epigenetic Mechanisms 
Activating or repressing H19 may be important as an epigenetic therapy for future 
treatment of epigenetic abnormalities in diseases.  In this section, we aim to highlight known 
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cases where H19 directly participates in either the repression or activation of transcription 
through direct epigenetic mechanisms.  First, we will examine H19 in the repression of genes 
and, second, in the activation of genes.  Finally, we will examine how H19’s role as an 
epigenetic modifier impacts chemotherapy resistance.  In these examples, H19 plays a clear role 
in affecting transcription through chromatin remodeling. 
In many examples, H19 recruits epigenetic modifiers, acting as a guide to repress gene 
expression.  Important for embryonic development, H19 controls at least nine imprinted genes 
(Igf2, Igf1r, Dlk1, Meg3, Slc38a4, Peg1, Dcn, Cdkn1c, and Gnas) in the mouse IGN (Monnier et 
al., 2013).  The control over some of these genes occurs by H19 interaction with methyl-CpG-
binding domain protein 1 (MBD1), a protein in the same family as MeCP2 (discussed earlier as a 
repressor of H19 expression).  MBD1 binds to methylated DNA to recruit HDACs and histone 
lysine methyltransferase (KMT)-containing complexes, SETDB1 and SUV39H1, silencing genes 
via H3K9 methylation, inducing chromatin compaction (Figure 1.2 A) (Monnier et al., 2013).  In 
a second example, H19 represses gene expression through the interaction with enhancer of zeste 
homolog 2 (EZH2), a H3K27 methyltransferase in a part of the polycomb repressive complex 2 
(PRC2) in bladder cancer.  H19 association with EZH2 results in the activation in Wnt signaling 
and recruitment of PRC2 to silence E-cadherin (Figure 1.2 B) (Luo et al., 2013).  Although, the 
direct H19 and EZH2 binding has not been determined in liver, EZH2 has been shown to silence 
tumor suppressor microRNAs in liver cancer and is upregulated in HCC (Au et al., 2012).  It 
would be interesting to examine H19’s role in HCC to determine if they are binding partners in 
this condition. 
H19 can also promote gene expression by acting as a guide for epigenetic modifying 
enzymes.  For example, H19 binds hnRNP U, part of a complex with RNA polymerase II and a 
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histone acetyltransferase, PCAF.  Histone acetylation results in the upregulation of genes within 
the miR-200 family.  Activation of the miR-200 family ultimately suppresses metastasis in HCC 
(Figure 1.3) (Zhang et al., 2013).  These examples highlight how H19 can both repress and 
activate gene expression by epigenetic mechanisms, making context crucial in understanding its 
functions. 
H19’s role as an epigenetic modifier may also be important in the study of a barrier in 
cancer treatment, chemotherapy drug resistance.  P-glycoprotein, an efflux transporter, is often 
upregulated in cancer cells.  This prevents cancer drugs from accumulating in cancer cells, 
thereby reducing their efficacy.  H19 may induce P-glycoprotein expression by regulating MDR1 
promoter methylation (Tsang and Kwok, 2007).  In a doxorubicin-resistant hepatocellular 
carcinoma cell line, R-HepG2, it was found that knockdown of H19 resulted in an increase of 
promoter methylation at the MDR1 promoter.  Establishment of the mechanism, by which H19 
regulates the promoter methylation status of efflux transporters in chemotherapy drug resistance, 
will further define H19’s role to influence gene expression as an epigenetic modifier. 
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Figure 1.2.  Epigenetic regulation by H19.  H19 acts to repress genes within the imprinted gene 
network, such as IGF2.  H19 binds MBD1.  MBD1 then binds methylated DNA and then recruits 
histone lysine methyltransferases (KMTs) to silence these genes by chromatin compaction (A).  
H19 silences E-cadherin.  H19 binds EZH2, a H3K27 methyltransferase part of the PRC2, 
causing downregulation of E-cadherin (B). 
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Figure 1.3.  H19 can also activate gene transcription.  H19 binds hnRNP U, which is a member 
of the complex with RNA Polymerase II and PCAF, a histone acetyltransferase.  H19 binding 
results in the upregulation of the miR-200 family of microRNAs through histone H3 acetylation. 
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1.5.4 The Roles of H19 in Normal Liver Functions 
1.5.4.1 The Roles of H19 in Liver Development 
The liver is an essential organ for life.  Hepatocytes, the main parenchyma of the liver, 
comprise almost 80% of the adult liver’s total mass (Kmiec, 2001).  The remaining mass 
includes cholangiocytes, sinusoidal endothelial cells, stromal cells, Kupffer cells, and stellate 
cells.  The liver has many important biological functions, such as detoxification, modification 
and excretion of exogenous and endogenous substances, the synthesis of cholesterol, bile salts, 
and phospholipids, and blood glucose regulation (VanPutte et al., 2013).  The liver is also the 
major organ for hematopoiesis in the fetus (Georgiades et al., 2002).  We will examine H19’s 
role in some of these major processes, including its role when these processes are not functioning 
normally in disease. 
Many studies have shown that lncRNAs are important regulators of normal liver 
development.  LncRNAs are differentially expressed throughout different stages of development 
from embryogenesis to adult life.  Our lab has previously characterized, using whole 
transcriptome analysis, the expression patterns of liver lncRNAs by RNA-sequencing in mice 
before birth to adult (Peng et al., 2014). We have discovered that there are three major oncogenic 
patterns of differential expression and potentially a functional transition of lncRNAs that occur at 
the neonatal, adolescent, and adult stages, implying their importance in liver maturation.  H19 
was found to be the most differentially expressed annotated lncRNA between fetal and adult 
liver.  Mechanistically, H19 expression is drastically silenced at the postnatal age due to 
transcriptional repression by zinc fingers and homeoboxes 2 (Zhx2) protein (Perincheri et al., 
2005), the same protein that regulates alpha-fetoprotein, which led to H19’s initial discovery 
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(Pachnis et al., 1984).  This intricate temporal control indicates H19 is a regulator of liver 
development. 
H19 controls liver growth and potentially the decline of the hematopoietic role of the 
liver after birth through the IGN.  The decline of the expression of genes within the IGN 
coordinates the deceleration of organ growth, including the liver after birth (Lui et al., 2008).  As 
previously described, H19 has been shown to regulate genes within the IGN by epigenetic 
mechanisms (Monnier et al., 2013), indicating that H19 has a major influence on development.  
Igf2 and Dlk1, both in the IGN, are also important for hematopoiesis (Zhang and Lodish, 2004; 
Sakajiri et al., 2005), and the liver is the main site of hematopoiesis during birth.  The repression 
of Igf2 and Dlk1 by H19, which has been shown experimentally, indicates that H19 is potentially 
responsible for the developmental switch of the liver starting as a hematopoietic organ to an 
organ that focuses mainly in metabolism.  H19’s control over the IGN leads to many 
implications on its role in regulating liver development. 
H19 also regulates the proliferation of liver in development by Wnt signaling.  The Wnt 
signaling pathway is critical for postnatal liver growth (Apte et al., 2007).  H19 inhibits 
proliferation in fetal liver by inhibiting the canonical Wnt signaling pathway through inhibition 
of its major intracellular signal transducer, β-catenin (Wang et al., 2016b).  H19 can block the 
interaction of hnRNP U with actin, leading to transcriptional repression of genes involved in the 
Wnt signaling pathway (Wang et al., 2016b). Despite these two mechanisms, there is also 
evidence of H19 activating Wnt signaling, albeit in a different context and cell type: bladder 
cancer (Luo et al., 2013).  These examples show how H19 can act by different mechanisms to 
affect one master regulation pathway.  In the context of liver proliferation in development, H19 
appears to be a negative regulator of Wnt signaling. 
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The microRNA encoded within H19, miR-675, is also potentially important for 
development.  The RNA binding protein, HuR, blocks the processing of miR-675 from H19, but 
during gestation, HuR is downregulated, causing miR-675 expression.  Overexpression of miR-
675 in extraembryonic cell lines causes reduced proliferation.  Mechanistically, miR-675 inhibits 
Igf1r, and this inhibition can limit placental growth (Keniry et al., 2012). 
H19 is also implicated in abnormal fetal development, regulated by epigenetic 
mechanisms.  Developmental-specific methylation occurs at different regions around the 
H19/IGF2 locus in DMRs in promoters for both genes (Li et al., 1998).  DNA methylation of 
imprinted genes is first erased in primordial germ cells and reestablished later in the formation of 
gametes (Arnaud, 2010). In vitro fertilization (IVF) may disrupt normal embryonic and fetal 
growth, causing abnormal gene expression in liver.  Through disruption of epigenetic regulatory 
networks, errors on both the maternal and paternal alleles occur at the H19 DMR and the IGF2 
DMR2, respectively.  H19 is significantly downregulated, and IGF2 is upregulated in livers of 
mice at birth and three weeks of age if they were conceived via IVF.  At 1.5 years of age, mice 
conceived via IVF had significantly lower H19 and IGF2 expression in liver.  IVF causes 
hypomethylation at the H19 DMR, indicating that early life manipulation affects vulnerability to 
differential methylation.  In humans, growth disorders are higher and birth weights are lower in 
newborns conceived by IVF (Le et al., 2013).  This study highlights the importance of 
maintaining proper methylation statuses at the H19/IGF2 locus in development. 
1.5.4.2 The Roles of H19 in the Regulation of Xenobiotic Metabolism and Transport 
The liver is the most important organ for metabolizing endogenous compounds and 
xenobiotics, including drugs.  The liver contains multiple classes and families of metabolizing 
enzymes.  These enzymes participate in reactions to make xenobiotic compounds more water 
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soluble and capable of clearance through excretion in the urine or transportation into the bile.  
For example, the cytochrome P450 enzymes are a class of phase I enzymes.  They typically 
function as monooxygenases that insert oxygen into molecules, making them more water soluble 
and easier to clear from the body (Werck-Reichhart and Feyereisen, 2000).  
Phase II enzymes are drug-metabolizing enzymes capable of conjugation reactions (Jancova et 
al., 2010).  Drug transporters are also important for clearing xenobiotics from the body 
(Klaassen, 2002).  Efflux transporters, such as MDR1, are upregulated in HCC (Bonin et al., 
2002), often inhibiting chemotherapy drugs from effectively inhibiting cancer cells. Currently, 
there is little research on how lncRNAs affect xenobiotic metabolizing enzymes, particularly in 
mammalian systems, indicating a knowledge gap and a potential area for further study. 
H19 affects drug transporter and phase II conjugation, resulting in alteration of the 
metabolism and disposition of drugs.  H19 is overexpressed in a number of drug-resistant cell 
lines, including doxorubicin-resistant liver cancer cells (Tsang and Kwok, 2007) and cisplatin-
resistant ovarian cancer A2780-DR cells (Zheng et al., 2016). In both studies, knockdown of H19 
expression results in restored chemotherapeutic sensitivity.  The doxorubicin-resistant liver 
cancer cells exhibit an overexpression of the transporter MDR1.  Sensitivity is restored by 
methylation of the MDR1 promoter, causing its repression and inability to efflux the drug (Tsang 
and Kwok, 2007).  In the cisplatin-resistant ovarian cancer cells, H19 knockdown coincided with 
a reduction of glutathione S-transferase P1 (GSTP1), responsible for cisplatin inactivation 
(Zheng et al., 2016). Examination of changes in phase II glutathione conjugation and in drug 
transporters after H19 knockdown in liver cancer cell lines should further be explored, as these 
enzymes are important for clearing drugs and for the accumulation of drugs in cancer cells. 
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Although H19 has not been directly linked to the regulation of phase I metabolism 
enzymes, current research may support H19 having a role.  Gene expression profiles of P450 
enzymes change in the developing liver, and normal adult P450 expression is not established in 
mice until a specific postnatal age (Hart et al., 2009).  This change corresponds inversely with 
the expression pattern of H19 in liver.  ZHX2, described earlier as the repressor that targets H19 
for silencing in postnatal liver, also regulates sexually dimorphic, developmentally-regulated 
P450 genes in liver, including Cyp2a4, Cyp2b13, and Cyp4a12 (Townsend Creasy et al., 2016). 
Human CYP2A6 has the highest homology to mouse Cyp2a4, and CYP2A6 is responsible for 
metabolizing nicotine, carcinogens, and several pharmaceuticals.  Although there is no direct 
link of H19’s role in regulating these enzymes, its direct repressor has been described as 
important.  Further research is needed to determine if H19 regulates phase I metabolism and its 
implication on the metabolism of drugs, especially in the fetus and in postnatal liver.  This 
research will aid our understanding of how the fetus, neonates, and children handle drugs while 
they express H19 compared to adults without H19 expression in liver. 
1.5.5 The Roles of H19 in the Progression of Liver Diseases 
1.5.5.1 The Roles of H19 in the Development of Steatosis, Fibrosis, and Cirrhosis 
Targeting H19 in cholestatic liver fibrosis may reduce liver injury.  Accumulation of bile 
acid leads to cell injury, causing inflammation and fibrosis (Zollner and Trauner, 2009).  One 
cause of cholestasis is the buildup of cytotoxic bile acids due to bile acid synthesis and 
accumulation from blocked uptake into hepatocytes and inhibited renal excretion via NTCP 
(Zhang et al., 2016).  Although H19 does not seem to play a role in bile acid synthesis, its direct 
repressor, SHP, represses CYP7A1 and CYP8B1 after activation by FXR.  The antiapoptotic 
protein, BCL2, appears to have an overarching control over SHP and H19.  Mechanistically, 
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BCL2 overexpression results in a drastic 47-fold increase in H19 due to its degradation of the 
SHP repressor.  The molecular basis, by which H19 regulates liver fibrosis, has yet to be 
completely determined.  Despite not directly controlling P450s or FXR expression, the 
knockdown of H19 still partially rescues BCL2-induced liver injury (Zhang et al., 2016).  This 
partial rescue of injury may be an important observation for the treatment of cholestatic liver 
fibrosis pointing to H19 as a target for potential therapy. 
Another condition, non-alcoholic fatty liver disease (NAFLD), occurs when fat is 
deposited in liver, steatosis.  LncRNAs, including H19 and its co-regulated protein-coding 
partner, IGF2, may play important roles in this disease progression.  One study found that 
approximately 500 lncRNAs were upregulated and 1,200 lncRNAs were downregulated in 
human livers of patients with NAFLD compared to healthy livers (Sun et al., 2015). Another 
study links H19 to steatosis through PLIN2, a member of the lipid droplet protein family that is 
markedly increased in fatty liver.  When PLIN2 was inhibited, a 548-fold increase in H19 was 
observed with a significant decrease in liver triglycerides (Imai et al., 2012).  In another study, 
p62, a binding protein of IGF2 mRNA, was highly expressed in diseased liver.  When 
overexpressed in mice, p62 can induce the steatotic phenotype (Tybl et al., 2011), including a 
two-fold increase in triglycerides compared to wild type (Laggai et al., 2013).  It was first found 
that p62 expression did not induce inflammation, showing correlation to NAFLD, but not 
progressing fully to NASH.  However, other researchers have reported p62 overexpression 
resulting in the activation of NF-κB, suggesting an increased inflammatory response and 
progression to NASH (Simon et al., 2014). 
NAFLD can progress to its most extreme form, non-alcoholic steatohepatitis (NASH).  
NASH is the major cause of cirrhosis of the liver.  Cirrhosis, a disease where the liver does not 
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function properly due to long-term damage, resulted in 1.2 million deaths in 2013 (Mortality and 
Causes of Death, 2015).  Cirrhosis is usually caused by alcohol or hepatitis B or C.  Fibrosis, or 
scarring of the liver, and steatosis, fatty liver, often precedes cirrhosis.  Hepatic stellate cells are 
the main extracellular matrix producing cells and upon activation can promote fibrosis and 
cirrhosis.  H19 is known to sequester miR-874 in the intestinal barrier (Su et al., 2016b), and this 
microRNA is upregulated in hepatic stellate cells upon activation, potentially implicating a 
mechanism that needs further study (Kitano and Bloomston, 2016). Furthermore, whole 
transcriptome RNA-sequencing analysis was performed in cirrhotic livers compared to normal 
healthy tissue, and H19 was discovered to be upregulated in cirrhotic liver tissue (Esposti et al., 
2016).  Only correlation of H19 to this disease has been reported, and these studies do not 
examine mechanism, again indicating a need for further research.  It is clear, however, that 
lncRNAs, including H19, are involved in NAFLD and potentially to its progression to NASH. 
1.5.5.2 The Roles of H19 in the Regulation of Diabetes 
The body needs to maintain blood sugar at precise levels and the liver is a major site of 
glucose regulation.  In times of low blood sugar, the alpha cells of the pancreas secrete glucagon, 
stimulating the liver to release glucose stores and induce the production of more glucose through 
gluconeogenesis.  Conversely, glycogenesis, the process of generating glycogen from glucose, is 
stimulated by insulin generated in the beta cells of the pancreas when blood glucose levels are 
high.  Insulin promotes the liver and muscle to take up blood glucose, effectively dropping blood 
glucose levels.  Diabetes mellitus (DM) is a disease caused by prolonged increased blood sugar 
levels due to dysregulation of these processes.  DM is caused by either the pancreas not 
producing enough insulin (type I DM) or the body, including the liver, not properly responding 
to insulin (type II DM) (Roder et al., 2016).  
43 
 
There is superficial evidence for H19's significance in type II DM.  Smooth muscle cells 
cultured in the presence of insulin express a five-fold increase in H19 than when cultured in 
media alone (Han et al., 1996).  This indicates that H19, at the very least, responds to changes in 
insulin.  Mice with a whole-body knockout of H19 expression (through targeted deletion at the 
maternal allele) are 27% heavier (Leighton et al., 1995a) due to this mutation, which also results 
in biallelic expression of IGF2 (Ripoche et al., 1997) and improper growth after birth, 
predisposing them to type II DM (Eriksson et al., 2003). These observations begin the story, but 
more convincing mechanistic studies examining changes in the epigenetics profiles of H19 and 
IGF2 are needed to fully determine H19’s role. 
Epigenetic phenomenon in the liver at the ICR between H19 and IGF2, and H19 
expression are proposed to play a role in type II DM.  In a study examining differential mRNA 
expression levels and patterns of DNA methylation in liver tissue, significant differences were 
observed between normal patients and patients with type II DM, such as an increase in H19 
expression and the degree of methylation at its gene locus (Nilsson et al., 2015).  Another study 
reported a significant degree of hypomethylation at the H19 locus in an insulin-resistant female 
(Murphy et al., 2012).  Currently, there is little research on the mechanism of insulin resistance 
in the liver regarding H19; only associations regarding expression and methylation status have 
been characterized.  Because the liver is a major site of insulin resistance in type II DM, there is 
the need for further research in liver, specifically.  There is also significant evidence that H19 is 
important in other tissues, such as insulin resistance in muscle and insulin production in the 
pancreas due to glucose intolerance. 
H19 plays a role in both humans and mice with type II DM in the muscle.  H19 was 
shown to be significantly decreased and to act as a decoy for microRNA let-7 (Gao et al., 2014).  
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H19 acts as a sponge that sequesters let-7, which targets genes, such as Insr and Lpl, to inhibit 
the insulin-PI3K-mTOR pathway.  Downregulation of H19 in diabetic muscle limits let-7 
sequestration, subsequently increasing inhibition of the pathway and promoting insulin 
resistance.  Let-7 has also been reported to destabilize and downregulate H19 as a protective 
mechanism in hyperinsulinemic conditions in non-diabetic muscle cells via a KSRP-dependent, 
insulin/PI3K/AKT signaling system.  Chronic downregulation of H19 limits glycogenesis and 
interferes with normal glucose metabolism (Gao et al., 2014).  Examining how H19 interacts 
with let-7 in liver may yield parallel mechanisms.  Let-7 is expressed in liver, and as stated 
earlier, H19 expression was shown to increase in patients with type II DM.  Another example of 
H19 sequestering microRNAs affecting important signaling pathways important for glucose 
regulation was studied in tendon-derived stem cells.  Here, H19 directly targets miR-29b-3p (Lu 
et al., 2016a).  This microRNA has also been shown to lead to dysregulation of insulin/PI3K-
AKT signaling in both the livers and pancreases in a mouse model that develops hyperglycemia 
(Kwon et al., 2014).  Translational research is needed to further elucidate H19’s role on these 
targets in liver. 
The pancreas is another site of differential methylation of the H19 ICR in mice exposed 
to high intrauterine glucose, resulting in diabetes.  Researchers induced diabetes in pregnant 
females.  As a result, their pups received a high exposure to glucose, leading to low expression 
levels of H19 and IGF2.  Low expression was due to hypermethylation of the ICR in the pups' 
pancreatic islets.  Low expression of H19 and IGF2 was also observed in the sperm of these 
mice.  This indicates high intrauterine glucose exposure can cause glucose intolerance, and this 
disease state can be passed down further to future offspring (Ding et al., 2012).  This study 
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provides a compelling mechanism for the inheritance of childhood diabetes with H19 as a 
significant factor. 
H19 may act differently in different tissues impacting diabetes in a multifaceted fashion.  
Diabetes linked to H19 in liver has been severely understudied, despite being an important organ 
in insulin resistance.  H19 has been shown to regulate glucose intolerance and insulin resistance, 
but studies have mainly focused on muscle and the pancreas.  Discovering how H19 participates 
in this disorder in the liver will allow for a more systemic understanding of the problem. 
1.5.5.3 The Roles of H19 in Hepatocellular Carcinoma 
Hepatocellular carcinoma (HCC) is a serious disease with few treatment options, needing 
more targeted therapies for better treatment.  HCC is the fifth most common cancer (Parkin et al., 
2005) and the most common liver cancer, accounting for 75% of all primary cases (Ahmed and 
Lobo, 2009). HCC has many known risk factors, including hepatitis B and C (Tanaka et al., 
2011). Treatment includes liver transplantation with a survival rate ranging from 67% to 91% 
from studies performed in the late 2000s (Vitale et al., 2007), pharmacological intervention with 
a tyrosine kinase inhibitor, sorafenib, for inhibiting tumor-cell proliferation (Llovet et al., 2008) 
or surgical resection (Ang et al., 2015). HCC is the most studied liver disease, and there have 
been many newly-discovered roles that various lncRNAs play in its progression, paving the way 
for new drug targets. 
H19’s importance has been widely implicated in HCC; however, reports are inconsistent 
in its role of promoting cancer as an oncogene or acting as a tumor suppressor.  Raveh et al. 
recently published an excellent extensive review regarding H19’s role in cancer initiation, 
progression, and metastasis, where they aimed to resolve conflicting literature (Raveh et al., 
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2015).  There are many differences in HCC compared to other cancers, so the need to 
concentrate attention on mechanisms specific to liver is important.  For instance, there is a 
difference in how p53, the tumor suppressor regarded as guardian of the genome, behaves in 
different cancers.  It appears p53 does not control the reemergence of H19 expression in HCC as 
it functions in other cell types.  In HeLa cells derived from cervical cancer, repression of H19 by 
p53 was observed at the H19 promoter (Dugimont et al., 1998).  In the thymus, p53 also 
suppresses H19 by regulating DNA methyltransferase expression profiles.  This causes 
methylation at the H19 ICR, leading to changes in H19 and IGF2 expression (Park et al., 2005).  
In the liver, however, p53 does not contribute to the methylation status of the ICR, and 
insignificant changes in H19 and IGF2 expression were observed after knockout of p53 (Park et 
al., 2005).  This example highlights how H19 is regulated differently between different cancers 
and cell types, as well as the need to focus on H19 in the context of HCC. 
Many examples discuss H19 promoting cancer.  The reemergence of H19 and IGF2 
expression in HCC alone implicates them as positive regulators.  After H19 and IGF2 are 
downregulated at the postnatal ages, they are both reactivated to be expressed in adult livers with 
HCC (Cariani et al., 1988; Ariel et al., 1997; Kim and Lee, 1997).  Both genes exhibit biallelic 
expression due to a dysregulation of their imprinting (Kim and Lee, 1997).  H19 re-expression 
might be explained by repression of Zhx2, the gene that silences H19 at the postnatal age, in 
HCC, through promoter methylation (Lv et al., 2006).  Targeting H19 expression may be a 
potential therapy, as H19 knockdown in cancer cell lines, such as Hep3B, has been shown to 
decrease tumor weight and tumor volume (Matouk et al., 2007). 
HCC tumorigenesis promotion is also regulated by miR-675 through various 
mechanisms.  First, miR-675 directly increases proliferation in HCC by affecting cell cycle 
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regulation through the inhibition of retinoblastoma protein (Hernandez et al., 2013).  Second, 
miR-675 upregulates H19 expression.  Molecularly, miR-675 inhibits HP1α causing histone 
modifications (reduced H3K9 trimethylation, reduced H3K27 trimethylation and increased 
H3K27 acetylation) at the EGR1 promoter, enhancing its transcription.  EGR1, in turn, 
upregulates H19, activating PKM2.  Ultimately, this results in tumor formation and the 
promotion of angiogenesis (Li et al., 2015a). 
Tumors transitioning from benign to malignant undergo angiogenesis, and H19 impacts 
this area of tumorigenesis, as well.  To stimulate angiogenesis, H19 has been found to be 
released from the exosomes of CD90+ liver cells to endothelial cells.  H19 then induces the 
expression of various transcripts, such as VEGF, known to stimulate angiogenesis in endothelial 
cells (Conigliaro et al., 2015).  Angiogenesis inhibitors are used in the treatment of cancer 
pointing to H19 as a potential target in this example.  Previously mentioned sorafenib displays 
antiangiogenic activity outside of its main mechanism to suppress tumor growth (Gotink and 
Verheul, 2010).  Suppressing H19 may also help to treat HCC through inhibition of 
angiogenesis. 
Other lncRNAs regulate liver cancer in tandem with H19.  Recent studies have suggested 
that initiation of HCC can start with progenitor cells of the liver rather than the parenchyma.  The 
lncRNA CUDR accelerates liver cancer stem cell growth by binding cyclin D1 and, as a 
complex, binding both the promoters of H19 and c-Myc. Increased expression of H19 promotes 
excessive TERT enhancing telomerase activity, and c-Myc increases liver cancer stem cell 
proliferation (Pu et al., 2015). These well-defined mechanisms support the role of H19 being an 
oncogene.  However, H19 can also assume a role in contrary to the promotion of HCC.  There is 
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increasing evidence that supports H19 as being a tumor suppressor acting to inhibit metastasis 
(Hernandez et al., 2013; Zhang et al., 2013). 
1.5.5.4 The Roles of H19 in the Epithelial-to-Mesenchymal Transition 
Tumor metastasis requires the ability of cancer cells from a primary site to invade a 
secondary site.  In order for this to occur, the cancer must transition from its originating cell type 
to a cell type capable of differentiating into various other cell types.  EMT occurs when epithelial 
cells become mesenchymal cells with this capability.  An original cell loses its polarity and cell-
to-cell adhesion, gaining migratory and invasive properties.  This gives the cell the ability to 
differentiate back into a cell type of the tissue it has invaded. 
Epigenetic changes are involved in cancer metastasis in HCC, and H19 has been shown 
to impact pathways, resulting in epigenetic changes leading to tumor suppression.  The next 
example was previously discussed in a prior section examining H19 regulation by epigenetic 
mechanisms.  H19 suppresses metastasis by repressing markers for EMT through the regulation 
of the miR-200 family.  The markers for EMT examined (E-cadherin, cytokeratin-8, cytokeratin-
19, and claudin 1) were increased following H19 knockdown, indicating H19 inhibits EMT.  
H19 accomplishes this via histone acetylation to activate the miR-200 pathway after complexing 
with hnRNP U/PCAF/RNA Pol II (Zhang et al., 2013).  The miR-200 family was found to 
enhance E-cadherin expression in two different HCC cell lines (Hung et al., 2013).  The miR-200 
family achieved this enhancement by directly targeting E-cadherin’s transcriptional repressors, 
ZEB1 and ZEB2, as determined in NMuMG murine mammary epithelial cells (Korpal et al., 
2008).  E-cadherin expression enhancement hinders EMT in an in vitro model of EMT induced 
by transforming growth factor-β in NmuMG cells.  E-cadherin expression also decreases motility 
in different cell lines derived from cancer, including HepJ5 cells, an HCC cell line (Hung et al., 
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2013).  Again, the H19 transcript is not fully responsible for its function in EMT, as miR-675 
also plays a role.  Evasiveness is reduced by inhibiting Twist1, a key mediator of EMT 
(Hernandez et al., 2013).  Despite the previous assumption that H19 promotes HCC by 
increasing proliferation and angiogenesis, H19 opposes metastasis.  Understanding this 
complicated interplay between H19 acting as an oncogene and a tumor suppressor results in a 
more complex, but clearer picture of how H19 participates in each role. 
1.5.6 Targeting H19 for Development of Therapeutic Approaches for Liver Diseases 
New therapies to treat liver diseases are needed and more research will need to follow 
before effectively utilizing H19.  Currently, there is very little research connecting H19 to 
diseases, such as type II DM or NAFLD and NASH, and more studies are needed before 
therapies can be designed utilizing H19 as a target.  However, there is exciting research using 
H19 to treat HCC, which is greatly needed.  Currently, there is only one approved 
pharmacological intervention to treat HCC, sorafenib.  In 2008, it was found that survival is 
extended only three months for patients with advanced HCC after treatment with sorafenib 
(Llovet et al., 2008).  H19 has been suggested as a candidate tumor marker for HCC (Ariel et al., 
1998).  Although diagnosis is an important step to treatment, it is more powerful to think of 
directly targeting or using H19 in a gene therapy approach.  DTA-H19 is a plasmid containing a 
diphtheria toxin ‘A’ chain and expression is driven by the H19 promoter.  Toxicity is highly 
selective, because cancerous cells have been shown to activate the H19 promoter and normal 
healthy cells do not.  Current research has displayed a delay in tumor growth and tumor 
regression of colon adenocarcinoma metastases in the livers of rat (Sorin et al., 2011), as well as 
clinical trials for bladder and ovarian cancer by the company BioCancell (Jerusalem, Israel)  
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(http://www.biocancell.com/lead-program/bc-819/).  This indicates the potential for novel gene 
therapies using lncRNAs, such as H19, promising new drug modalities. 
Drug resistance is a major problem in chemotherapy.  In the two examples regarding 
chemotherapy drug metabolism and transport presented earlier, there is promise in targeting H19.  
Often, MDR1 is overexpressed, leading to increased efflux of cancer drugs and inefficacy.  
Targeting H19 in cancer therapy may reduce MDR1-associated drug resistance, as H19 
knockdown has been shown to suppress MDR1 expression.  Suppression is through increasing 
MDR1 promoter methylation, leading to increased accumulation and efficacy/toxicity of 
doxorubicin in doxorubicin-resistant R-HepG2 cells (Tsang and Kwok, 2007).  The cisplatin-
resistant cell line A2780-DR cells also become chemosensitive with knockdown of H19 (Zheng 
et al., 2016).  These two examples are potentially important in the fight against drug resistance 
and treating cancers. 
1.5.7 Further Considerations at the H19 Locus, 91H and HOTS 
Genes overlapping the H19 gene sequence with transcriptional activity have been 
discovered other than H19’s well-studied microRNA, miR-675 (Figure 1.1).  91H and H19 
opposite tumor suppressor (HOTS) are both antisense to H19 and have been discussed in the 
context of disease.  Their roles in liver have yet to be determined, leaving the door open for 
further research.  Due to their implication in other diseases, their sharing of sequence, and either 
their similar regulation with or regulation of H19, it is important to discuss them here. 
91H in human is a potentially 120 kb long transcript coded antisense to H19.  At full-
length, it overlaps the entire H19 gene, the ICR between H19 and IGF2, and the previously 
discussed enhancers that drive expression of H19 and IGF2 (Berteaux et al., 2008).  Like H19, 
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91H is also upregulated in a number of cancers (Berteaux et al., 2008; Deng et al., 2014; Gao et 
al., 2015; Xia et al., 2016), and mirrors studies examining H19’s role as a tumor suppressor and 
an oncogene with no clear consensus of the overall general mechanism.  91H is also important 
for the regulation of IGF2 expression.  Knockdown studies have shown that 91H contributes to 
IGF2 expression at the paternal allele (Berteaux et al., 2008).  91H is also responsible for 
maintaining H19/IGF2 imprinting and preventing DNA methylation at the H19/IGF2 locus (ICR 
and H19 promoter) on the maternal allele, potentially by binding and masking these sites, driving 
H19 and IGF2 expression (Vennin et al., 2016).  Outside of controlling imprinting, 91H can also 
directly activate a promoter of IGF2.  This activation can be counteracted by H19 (Tran et al., 
2012).  In order to develop future targets for therapies, it may be important to understand these 
mechanisms of 91H that have a direct effect on H19 expression, as well as 91H’s role in normal 
liver function, including its potential to cause liver disease. 
HOTS is another gene transcribed from the H19 locus that overlaps all but the first exon, 
first intron, and most of the second exon of H19 in human.  HOTS is maternally expressed and 
imprinted like H19, but unlike H19, it codes for a protein.  When overexpressed, HOTS inhibits 
various tumor types, and knockdown of HOTS results in tumor growth.  In samples of Wilms 
tumors, it was observed that a loss of imprinting at the locus that results in biallelic expression of 
IGF2 also silences of HOTS.  This led the authors to conclude that HOTS is a tumor suppressor 
(Onyango and Feinberg, 2011).  With little research on this transcript and its protein, it is 
difficult to assume that it is a useful target in therapy.  However, targeted overexpression or gene 
therapy using HOTS may be useful to suppress cancer.  As more information was discerned over 
the years studying H19, its role in disease was discovered to be immensely complex.  The same 
could be true in further investigations of both 91H and HOTS. 
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1.5.8 Conclusions 
LncRNA research is a relatively new focus.  Since H19 was one of the first lncRNAs to 
be identified and characterized, there is an abundant amount of research depicting its various 
roles.  The epigenetic regulation of H19 is unique and complex, being an imprinted gene 
containing a regulatory region that is differentially methylated depending on the parental origin.  
H19 participates in normal liver functions, such as development, and its dysregulation occurs in 
many liver disease, including HCC, type II DM, NAFLD, NASH, and cholestatic liver fibrosis.  
LncRNAs, including H19, have unique regulatory abilities, capable of binding proteins.  They 
are also capable of participating in epigenetic modification of genes to affect gene expression in 
numerous signaling pathways or are direct effectors of processes in normal function and disease.  
Many mechanisms have been presented, indicating H19 is a complex actor with roles in many 
organ systems, times of development, and in many disease states.  Its complex role in HCC has 
shown H19 to act as an oncogene regulating proliferation and angiogenesis while unusually also 
acting as a tumor suppressor inhibiting metastasis.  As the science progresses and gives us new 
insights into how lncRNAs and H19 control normal liver function and disease, therapies to treat 
disorders will follow eventually to improve overall human health. 
 
Chapter 2: The Role of H19, a Long Non-coding RNA, in Mouse Liver Postnatal Growth 
2.1 Introduction 
Liver development requires both cell proliferation and differentiation.  Cell proliferation 
allows the liver to achieve its proper size in the body and cell differentiation allows the liver to 
attain proper functions.  Both of these events coincide concurrently during postnatal liver 
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maturation.  During this important, but understudied, phase of development, the liver undergoes 
a switch in functions.  In mouse, the liver becomes the major hematopoietic organ in the fetus 
between embryonic days 10 to 15 (Zorn, 2008).  After birth it matures into an organ primarily 
functioning in metabolism (Hata et al., 2007).  Throughout ontogenesis until the liver is fully 
mature, changes occur in the expression profiles of many protein-coding genes involved in 
important liver functions (Li et al., 2009a; Si-Tayeb et al., 2010), including the regulation of 
energy metabolism (Renaud et al., 2014) and drug metabolism and transport (Collardeau-
Frachon and Scoazec, 2008; Cui et al., 2012; Peng et al., 2012; Lu et al., 2013; Peng et al., 
2013), which are responsible for important physiological functions of mature liver.  However, it 
is not fully understood what initiates this switch in functions. 
Proteins involved in signaling pathways and regulation of splicing are implicated in 
playing important roles in cell growth and differentiation during postnatal liver maturation.  
Knockout of mouse liver β-catenin, the intracellular transducer in Wnt signaling, results in a 
decrease in cell proliferation and a decrease in postnatal liver size (Apte et al., 2007).  Yes-
associated protein, the downstream effector of Hippo Kinase signaling, affects cell proliferation 
and regulates genes controlling hepatic functions including metabolism of bile acids and retinoic 
acids in mouse (Septer et al., 2012).  Two splicing factors are also known to affect postnatal liver 
maturation.  Epithelial splicing regulatory protein 2 is induced in hepatocytes during the 
postnatal age and controls the neonatal-to-adult switch of splice isoforms in gene transcripts 
involved in proliferation and differentiation that control hepatocyte maturation in both mouse 
and human (Bhate et al., 2015).  Serine/arginine-rich splicing factor 3 (SRSF3) alters splicing of 
genes that regulate glucose and lipid metabolism.  Knockout of Srsf3 in mice results in a decline 
in postnatal liver growth by a prolonged expression of fetal markers including persistence of 
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hepatic hematopoiesis (Sen et al., 2013).  Clearly, protein-coding genes are important for the 
functional switch in developing liver, however, the role of non-coding genes has largely been 
unexplored. 
Long non-coding RNAs (lncRNAs) also change in identifiable expression patterns 
throughout ontogenesis and potentially regulate liver development.  Recently, our laboratory 
examined the alterations of gene expression in lncRNAs during the liver’s functional transition 
through the prenatal stage to adult life in mice (Peng et al., 2014).  Three major ontogenic 
expression patterns were found with specific lncRNAs enriched at the neonatal, adolescent, and 
adult ages, indicating lncRNAs are developmentally regulated.  Expression of lncRNAs with 
their neighboring protein-coding genes was found to be correlated, indicating lncRNAs may 
regulate the expression of nearby protein-coding genes or share regulatory regions within their 
gene loci that coordinate their expression.  LncRNA H19 was found to be most differentially 
expressed lncRNA comparing prenatal expression to adult expression, and its cis protein-coding 
partner, IGF2, an important fetal growth factor, exhibits a similar temporal expression pattern.  
Despite being one of the most studied lncRNAs, H19’s role in liver development has not been 
fully determined. 
H19 is involved in normal liver physiology and is implicated in liver diseases (Pope et 
al., 2017).  H19 is expressed in liver during periods of increased cell proliferation, including liver 
regeneration after injury (Pachnis et al., 1984) and hepatocellular carcinoma (Ariel et al., 1997; 
Kim and Lee, 1997; Matouk et al., 2007).  H19 is also highly expressed in fetal liver during 
organogenesis.  In a human fetal liver cell line, H19 expression inhibits cell proliferation through 
Wnt signaling potentially to prevent overgrowth of fetal liver tissue (Wang et al., 2016a).  We 
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aim to test whether H19 plays a similar role in postnatal liver development, including both liver 
growth and liver maturation, using an H19 knockout mouse model (Ripoche et al., 1997). 
To test the effect of H19 on postnatal liver development, we used three genetically 
different mouse groups.  H19 is an imprinted gene uniquely expressed only from the maternal 
allele (Bartolomei et al., 1991).  Therefore, we carefully bred H19 knockout mice to generate 
mice heterozygous for the null mutation strictly controlling which parental allele H19 is fully 
intact or fully removed.  Using wild type mice (H19+/+), H19 maternal allele knockouts (H19M-
/P+), and H19 paternal allele knockouts (H19M+/P-), we were able to assess the role of H19 in 
postnatal liver development when H19 is expressed or not expressed from a specific allele.  
 
2.2 Materials and Methods 
2.2.1 Animals 
Eight-week-old C57BL/6 mouse breeding pairs were purchased from Jackson Laboratory 
(Bar Harbor, ME).  A permission for the use of previously characterized H19 knockout mice 
(Ripoche et al., 1997) was received from Dr. Luisa Dandolo.  A pair of H19 heterozygous male 
knockout mice (male-H19+/-) were received from Dr. Linheng Li’s laboratory at the Stowers 
Institute for Medical Research (Kansas City, MO, USA).  Mice were housed according to the 
animal care guidelines provided by the American Association for Animal Laboratory Sciences 
and were bred under standard conditions in the Laboratory Animal Resources Facility at the 
University of Connecticut (Protocol Number: A15-040).  The use of these mice was approved by 
the Institutional Animal Care and Use Committee, Office of Research Compliance.  A breeding 
scheme to generate paternal and maternal H19 knockout mice is illustrated in Figure 2.1.  Male 
heterozygous H19 knockout (H19+/-) mice (F-0) carrying the H19- on one allele with 
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undetermined parental origin were initially bred with wild type (H19+/+) mice of the same 
C57BL/6 background to generate F-1 male-H19+/- and female-H19+/- heterozygous.  The F-1 
female H19+/- were further bred with wild type mice to generate F-2 male and female maternal 
H19 knockout (H19M-/P+) offspring and the F-1 male-H19+/- were further bred with wild type 
mice to generate F-2 male and female paternal H19 knockout (H19M+/P-) offspring.  F-2 wild type 
(H19M+/P+) mice generated were used as controls.  Liver samples were collected at the following 
ages: day 5, 10 (neonatal), 15, 20, 30 (adolescent), and 60 (adult) after birth.  Livers from both 
males and females were collected for days 30 and 60 only, and livers from animals collected 30 
days before birth were not considered sexually mature and not separated by sex.  The livers were 
immediately frozen in liquid nitrogen and stored at -80°C or fixed in formalin. 
 
2.2.2 Human Liver Samples 
Human liver samples were procured and RNA-sequencing performed by Dr. J. Steven 
Leeder at Children’s Mercy Hospital (Kansas City, MO, USA).  A total of 60 livers ranging in 
age from before birth to 18 years after birth were analyzed for H19 and IGF2 expression. 
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Figure 2.1.  Breeding scheme diagram used to generate mice heterozygous for maternal and 
paternal H19 knockout.   
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2.2.3 Genotyping 
Ear or tail snips were collected from mice for DNA extraction.  PCR reactions were 
performed for identification of H19 deletion using a REDExtract-N-Amp Tissue PCR Kit 
purchased from Sigma-Aldrich (St. Louis, MO, USA).  Primers were designed using a 
PrimerQuest Tool from Integrated DNA Technologies (Coralville, IA, USA).  Sequences for the 
primers are forward 5’-CTGTTCATACTCCGTGGGATAG-3’, forward 
CAGACATTCATCCCGGTTACTT-3’, reverse 5’-CCTACCCATTACGAGCCTTAC-3’, and 
reverse 5’-GGGACCCATCTGTGTCTTGT-3’. 
 
2.2.4 Reverse transcription polymerase chain reaction (RT-PCR) 
Total RNAs were isolated from livers without gallbladders using TRIzol reagent from 
Life Technologies (Guilford, CT, USA) according to the manufacturer's protocol.  RNA 
concentrations were determined using a Nano Drop spectrophotometer from Nano Drop 
Technologies (Wilmington, DE, USA) at a wavelength of 260 nm.  The integrity of the total 
RNAs was evaluated on an Agilent 2200 Tape Station from Agilent Technologies (Santa Clara, 
CA, USA).  Gene expression at the RNA level of H19, miR-675-3p, miR-675-5p, IGF2, IGF1, 
IGF1R, β-catenin, cyclin D1, CYP3A16, CYP3A11, CYP2B10, CYP2C29, and GAPDH was 
determined by TaqMan assays from Life Technologies (Carlsbad, CA, USA) according to the 
manufacturer's protocol.  Data were analyzed by generation of cycling time (Ct) and delta Ct 
(ΔCt) values for all genes against GAPDH.   
 
2.2.5 Immunohistochemistry 
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Fresh liver tissues were fixed in 10% buffered formalin, embedded in paraffin, and 
sections were prepared and stained by the Connecticut Veterinary Medical Diagnostic 
Laboratory at the University of Connecticut (Storrs, CT, USA).  Immunohistochemistry was 
performed using antibodies against Ki-67 (rabbit polyclonal, Cat. No. ab15580) and proliferating 
cell nuclear antigen (PCNA) (rabbit polyclonal, Cat. No. ab18197) from Abcam (Cambridge, 
UK).  A secondary antibody conjugated to peroxidase allowed for color precipitation using a 
VECTOR NovaRED Peroxidase (HRP) Substrate Kit from Vector Laboratories (Burlingame, 
CA, USA).  Images were captured using an EVOS XL Core Cell Imaging System from Thermo 
Fisher Scientific (Waltham, MA, USA).  Positively stained nuclei were identified by using the 
ImageJ image processing program, version 1.50i, from National Institutes of Health (Bethesda, 
MD, USA) using a color brightness threshold with a signal intensity greater than or equal to 200. 
 
2.2.6 Western blotting 
Total proteins in liver lysates were isolated in RIPA Buffer and protein concentrations 
were determined by using a Qubit 2.0 Fluorometer by Invitrogen (Carlsbad, CA, USA) and the 
Lowry protein assay from Bio-Rad (Hercules, CA, USA) with absorbance at 750 nm using a 
Spectra MAX 190 from Molecular Devices (Sunnyvale, CA, USA).  Proteins were run on 
polyacrylamide gels using the Mini-PROTEAN Tetra System by Bio-Rad (Hercules, CA, USA) 
and transferred onto PVDF membranes.  Primary antibodies purchased from Cell Signaling 
Technology (Danvers, MA, USA) include IGF1R (1:1000, rabbit polyclonal, Cat. No. 3027), 
active β-catenin (1:1000, rabbit monoclonal, Cat. No. 8814), and total β-catenin (1:1000, rabbit 
monoclonal, Cat. No. 8480), and albumin (1:1000, rabbit polyclonal, Cat. No. 4929).  Primary 
antibodies against Wnt6 (1:1000, rabbit polyclonal, Cat. No. ab50030) was purchased from 
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Abcam (Cambridge, UK), α-fetoprotein (1:100, mouse monoclonal, Cat. No. MA5-12754) was 
purchased from Thermo Fisher Scientific (Waltham, MA, USA), and GAPDH (1:3000, rabbit 
polyclonal, Cat. No. G9545) was purchased from Sigma-Aldrich (St. Louis, MO, USA).  
Secondary antibodies, anti-rabbit IgG (1:1000, goat, Cat. No. 7074) and anti-mouse IgG (1:2000, 
horse, Cat. No. 7076), were purchased from Cell Signaling Technology (Danvers, MA, USA).  
Primary antibodies were conjugated to secondary antibodies conjugated to Horseradish 
peroxidase for detection using a ChemiDoc MP Imaging System from Bio-Rad (Hercules, CA, 
USA).   
 
2.2.7 Statistical analysis 
The data are shown as the mean ± standard deviation.  The significance of differences 
between means was determined using two-tailed unpaired Student’s t tests.  Statistical analyses 
were performed using Prism7, version 7.01 from GraphPad Software, Inc. (La Jolla, CA, USA).  
Differences were considered to be significant if p<0.05. 
 
2.3 Results 
2.3.1 Ontogenic expression of H19 and IGF2 in liver during postnatal maturation 
Previously generated RNA-sequencing (RNA-Seq) data (Peng et al., 2014) were used to 
examine H19 and IGF2 expression in wild type mouse liver (n = 36) at fetal, postnatal, and adult 
ages (Figure 2.2).  In mouse liver, H19 and IGF2 are highly expressed before birth and rise to 
their highest level of expression around the time of birth.  Expression levels precipitously decline 
at a postnatal age (approximately 20 days after birth) to nearly undetectable levels.  Adult mouse 
liver does not express H19 or IGF2.  
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Figure 2.2. Ontogenic expression of H19 and IGF2 in mice during postnatal maturation in 
liver. Expression of H19 (A) and IGF2 (B) was determined by RNA-Seq in mouse livers at ages 
-2, 0, 3, 5,  10,  15, 20, 30, 45, and 60 days after birth (n = 3 per group). Expression levels were 
measured as FPKM (Fragments Per Kilobase of transcript per Million mapped reads). Values are 
represented as mean ± S.D. 
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Figure 2.3. Ontogenic expression of H19 and IGF2 in human during postnatal maturation 
in liver. Expression of H19 (A) and IGF2 (B) was determined by RNA-Seq in human livers at 
ages before birth, less than 1 year, 1 to 6 years, 6 to 12 years, and 12 to 18 years  (n = 60). 
Expression levels were measured as TPM (Transcripts Per Million). Values are represented as 
mean ± S.D. 
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2.3.2 Abolishment of expression of H19 and miR-675 in H19 knockout mice  
Expression of H19 in livers of wild type, maternal H19 knockout, and paternal H19 
knockout mice was determined by RT-PCR at ages of 5, 10, 15, 20, 30, and 60 days after birth 
(Figure 2.4 A).  In all ages examined, H19 was not expressed in mice when the gene knockout 
was on the maternal allele despite the mice possessing an intact paternal allele (H19M-/P+).  Wild 
type mice (H19+/+) and heterozygous mice with H19 knockout on the paternal allele (H19M+/P-) 
exhibited similar expression of H19 at all ages. 
 
Two different conserved microRNAs, miR-675-3p and miR-675-5p, are produced from 
the first exon of H19 (Dey et al., 2014).  Using two different sets of primers directed against each 
miR-675 variant, their expression was determined by RT-PCR (Figure 2.4 B).  The pattern of 
means for both miR-675-3p and miR-675-5p expression followed H19 expression.  In most wild 
type individuals, expression was high at early ages until approximately 20 days after birth when 
levels precipitously decline.  Certain wild type individuals, despite normally expressing H19 at 
early ages, showed very little miR-675 expression, indicating large interindividual variation.  
Similar to H19, miR-675 was only expressed when H19 was intact at the maternal allele 
(H19M+/P+ and H19M+/P-) while knockout on the paternal allele (H19M+/P-) was inconsequential to 
miR-675 expression.  Essentially, H19 maternal allele knockout mice (H19M-/P+) are also miR-
675 knockout mice. 
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Figure 2.4. Expression of H19 and miR-675 RNA in mouse livers with H19 knockout on 
different parental alleles. RNA expression of H19 (A) and miR-675-3p and miR-675-5p (B) in 
mouse livers at ages 5, 10, 15, 20, 30, and 60 days after birth (n = 4 per group) was determined 
by RT-PCR in wild type (H19M+/P+), maternal H19 knockout (H19M-/P+), and paternal H19 
knockout (H19M+/P-) mice measured as fold-changes compared to the wild type.  Values are 
represented as mean ± S.D.  * p<0.05, ** p<0.01, *** p<0.001. 
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2.3.3 Changes of liver and body weights in the absence of H19 expression during postnatal 
maturation  
H19 impacts liver weight in the developing and adult male livers (Figure 2.5 A).  Liver 
weights are significantly higher only immediately after birth and in male adult mice not 
expressing H19.  Liver weights were significantly higher 5 days after birth in mice without H19 
expression (p<0.01).  No significant changes in liver weight were observed between wild type 
mice and mice not expressing H19 for ages 10, 15, 20, or 30 days after birth.  Adult males, but 
not adult females, have significantly higher (p<0.001) liver weights when measured 60 days after 
birth with H19 knockout on the maternal allele (H19M-/P+). 
 
H19 impacts total body weight in developing and adult mice in both males and females 
(Figure 2.5 B).  Despite H19 expression not significantly affecting liver weight in adolescent or 
adult female liver, body weights are significantly altered at both 30 (p<0.01) and 60 (p<0.001) 
days after birth, affecting also the liver/body weight ratio significantly at 30 days after birth 
(p<0.05).  Male liver/body weight ratios are not significantly affected by H19 expression (Figure 
2.5 C).  H19 also controls body weights when the liver is developing.  Body weights are 
significantly higher with no H19 expression at 5 days after birth (p<0.001) and 20 days after 
birth (p<0.05).  Both males and females had significant (p<0.001) increases in body weight at 60 
days after birth when H19 was not expressed.  Females, but not males, were significantly heavier 
at 30 days after birth (p<0.01) with no H19 expression through life. 
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Figure 2.5. Liver and body weights for mice with H19 knockout on different paternal 
alleles. Liver weights (A), body weights (B), and liver weight as a percentage of total body 
weight (C) were measured at the time of liver harvest from mice ages 5, 10, 15, 20, 30, and 60 
days after birth (n = 5-25).  Values are represented as mean ± S.D.  *p<0.05, **p <0.01, 
***p<0.001. 
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2.3.4 Changes in liver cell proliferation in the absence of H19 expression during postnatal 
maturation  
Corresponding data indicates liver weights are increased due to increases in cell 
proliferation throughout mouse development when H19 is not expressed.  Two markers of cell 
proliferation, Ki-67 and PCNA, were used to measure proliferating cells in the tissue sections 
(Figure 2.6).  When stained for Ki-67, livers from H19 maternal allele knockouts (H19M-/P+) 
show significantly more Ki-67 positive nuclei in livers of mice at ages 5 (p<0.001), 10 
(p<0.001), 20 (p<0.001), 30 in both males and females (p<0.001), and 60 only in males 
(p<0.001) days after birth.  PCNA was also used to measure cell proliferation in an independent 
experiment.  These data closely resemble Ki-67 staining results, indicating livers without H19 
expression proliferate more rapidly during development when compared to wild type.  In the 
maternal allele knockout mice, there were significantly more cells stained positive for PCNA at 
ages 5 (p<0.001), 10 (p<0.001), and 20 (p<0.001) days after birth.  Similar to Ki-67 results, 
significant differences were observed through postnatal liver development until age 15 days after 
birth, with significant differences again observed for age 20 days after birth.  Discordant 
measurements were observed between the two assays at ages 30 and 60 days after birth with Ki-
67 indicating significant changes for H19 maternal allele knockout mice (H19M-/P+) while PCNA 
did not stain significantly different at either of these ages.  Measurements for heterozygous 
paternal allele H19 mutants (H19M+/P-) resemble wild type (H19+/+). 
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Figure 2.6. Immunohistochemistry analysis for identification of proliferating cells in livers 
of mice with H19 knockout on different paternal alleles. Livers were fixed in formalin, 
embedded in paraffin, sectioned, and stained for (A) Ki67 or (B) PCNA for mice at ages 5, 10, 
15, 20, 30, and 60 days after birth (n = 3 per group). A representative image was taken from mice 
at age 20 days after birth.  Arrows indicate cells stained positive for (A) Ki67 and (B) PCNA. 
ImageJ software was used to count five sections per mouse.  Values are represented as mean ± 
S.D.  ***p<0.001.  
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2.3.5 Expression of IGF signaling and Wnt signaling genes in the absence of H19 expression 
during postnatal maturation  
Gene expression patterns for IGF2 and IGF1 were determined using RT-PCR for mice at 
ages 5, 10, 15, 20, 30, and 60 days after birth (Figures 2.7 A and B, respectively).  Both H19 and 
IGF2 were highly expressed at early ages until 20 days after birth when expression precipitously 
declines to undetectable levels and no expression persists through adult life.  IGF1 exhibits the 
opposite expression pattern, starting with low expression early in life, steadily increasing as the 
liver develops.  A significant increase (p<0.01) in IGF2 mRNA was found in H19 maternal allele 
knockout mice (H19M-/P+) compared to wild type (H19+/+) at 20 days after birth, indicating H19 
affects IGF2 expression.  However, at all other ages measured, no significant differences were 
found.  IGF1 mRNA was not impacted by the absence of H19 expression. 
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Figure 2.7. Expression of the fetal form IGF2 and adult form IGF1 RNA in mouse liver 
with H19 knockout on different parental alleles. RNA expression was determined by RT-PCR 
for (A) IGF2 and (B) IGF1 in mouse livers at ages 5, 10, 15, 20, 30, and 60 days after birth (n = 
4 per group).  Values are represented as mean ± S.D.  **p<0.01.  
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IGF1R expression was found to increase only at the protein level, but not at the mRNA 
level in H19 maternal allele knockouts (H19M-/P+) compared to wild type (H19+/+).  Although no 
significant differences were observed in mRNA expression at all ages measured (Figure 2.8 A), 
there was an increase in IGF1R protein expression when H19 was not expressed for each time 
point measured (Figure 2.8 B).  Levels of IGF1R protein expression were highly variable 
between individuals at each age and experimental groups. 
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Figure 2.8. Expression of IGF1R in mouse livers with H19 knockout on different parental 
alleles. (A) RNA expression was determined by RT-PCR in mouse livers at ages 5, 10, 15, 20, 
30, and 60 days after birth (n = 4 per group). (B) Protein expression was determined by Western 
blot for IGF1R for mice at ages 5, 10, 15, 20, and 60 days after birth.  Lanes 1-3 indicate wild 
type (H19+/+) individuals and lanes 4-6 indicate H19M-/P+ individuals.  Values are represented as 
mean ± S.D.   
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Wnt signaling was similarly only slightly impacted by the absence of H19 in mice.  No 
significant changes were observed at the mRNA level at all ages tested for either β-catenin or 
cyclin D1 (Figures 2.9 A and B, respectively).  Significant increases (p<0.05) were observed at 
the protein level for active β-catenin in mice at age 5 days after birth and in total β-catenin in 
mice at age 10 days after birth (Figure 2.9 C).  Protein expression was also analyzed for the 
ligand Wnt6, but no changes were observed. 
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Figure 2.9. Expression of Wnt signaling in mouse livers with H19 knockout on different 
parental alleles. RNA expression was determined by RT-PCR for (A) β-catenin and (B) cyclin 
D1 in mouse livers at ages 5, 10, 15, 20, 30, and 60 days after birth (n = 4 per group).  (C) 
Protein expression was determined by western blot for Wnt6, active β-catenin, and total β-
catenin for mice at ages 5, 10, and 15 days after birth (n = 2 per group).  Values are represented 
as mean ± S.D.  *p<0.05.  
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Chapter 3: The Role of H19, a Long Non-coding RNA, in Mouse Liver Postnatal 
Maturation 
 
3.1 Expression of P450 drug metabolizing enzymes in the absence of H19 expression during 
postnatal maturation  
Gene expression was determined for P450 enzymes in H19 paternal allele (H19M+/P-), 
H19 maternal allele knockouts (H19M-/P+), and wild type mice (H19+/+).  There were no 
significant differences in RNA expression for CYP3A16 (Figure 3.1 A) or CYP3A11 (Figure 3.1 
B).  A significant increase (p<0.05) was found in CYP2B10 in H19 maternal allele mutants 
(H19M-/P+) compared to wild type (H19+/+) for male mice aged 30 days (Figure 3.1 C).  
Significance was not found in females aged 30 days or at any other ages measured for CYP2B10.  
CYP2C29 expression is delayed in mice when H19 expression is not present early in life (Figure 
3.1 D).  A significant decrease (p<0.05) was detected at 15 days after birth in H19 maternal allele 
mutants (H19M-/P+).  Normally, as seen in wild type (H19+/+) and in paternal H19 allele 
knockouts (H19M+/P-), CYP2C29 begins to be slightly expressed at 15 days after birth.  However, 
when H19 is not expressed, CYP2C29 is not expressed until later in development and resumes its 
full normal expression at 20 days after birth. 
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Figure 3.1. Expression of P450 drug metabolizing enzymes in mouse livers with H19 
knockout on different parental alleles. RNA expression was determined by RT-PCR for (A) 
CYP3A16, (B) CYP3A11, (C) CYP2B10, and (D) CYP2C29 RNA in mouse livers at ages 5, 10, 
15, 20, 30, and 60 days after birth (n = 4 per group).  Values are represented as mean ± S.D.  
*p<0.05. 
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3.2 Expression of α-fetoprotein and albumin protein in the absence of H19 expression 
during postnatal maturation 
Liver postnatal protein expression for α-fetoprotein was examined in mice at ages 
corresponding to the decline of expression of H19 in normal wild type mice.  No significant 
differences in α-fetoprotein were observed between H19 maternal allele knockouts (H19M-/P+) 
and wild type (H19+/+) (Figure 3.2 A).  In mice aged 20 days after birth, no α-fetoprotein protein 
expression was found in liver for either test group.  As observed in IGF1R protein expression, 
large interindividual differences were found between the three mice tested in each group. 
 
Liver postnatal protein expression for albumin was examined in mice at the early ages of 
development.  Western blots indicate no significant difference in protein expression of albumin 
in livers of mice at ages 5 or 10 days after birth (Figure 3.2 B) for either test group.  As with α-
fetoprotein, there were large interindividual differences. 
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Figure 3.2. Protein expression of α-fetoprotein and albumin in mouse livers with H19 
knockout on the maternal allele. Protein expression was determined by Western blot for (A) α-
fetoprotein in mouse livers ages 15 and 20 days after birth, and (B) albumin in mouse livers ages 
5 and 10 days after birth.  Lanes 1-3 indicate wild type (H19+/+) individuals and lanes 4-6 
indicate H19M-/P+ individuals.  Values are represented as mean ± S.D.   
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Chapter 4: Summary 
4.1 Discussion 
Research on H19 in normal liver development has primarily focused on fetal 
development with little regard to H19’s role after birth despite this being a time when the liver is 
continually growing and is dynamically changing its function from being a hematopoietic organ 
to a metabolic organ.  When discovered, Pachnis et al. initially characterized H19 expression in 
mouse from before birth through the postnatal age until expression is terminated, by their 
observation, around 28 days after birth (Pachnis et al., 1984).  We have recapitulated their initial 
temporal expression pattern using modern techniques and expanded upon their seminal 
observations with a focus on H19’s role in postnatal liver maturation, including both liver growth 
and changes in the liver’s ability to achieve adult liver function. 
Liver growth is accelerated early in postnatal liver development when H19 is not 
expressed.  The overgrowth phenotype has been previously characterized for mice inheriting the 
H19-null allele from their mother (Leighton et al., 1995a).  Mice used in this study that were 
heterozygous containing a functional maternal allele but with a mutated paternal allele resemble 
homozygous wild type mice throughout our observations, as the paternal allele was 
inconsequential to H19 expression.  We observed the overgrowth phenotype by measuring both 
the total body and liver weights through the postnatal ages.  Early in life, liver weights are 
significantly affected when H19 is not expressed (Figure 2.5 A).  Coordinately, we also 
measured the level of cell proliferation in liver and found significant changes in positively 
stained nuclei for two different cell proliferation markers, indicating enhanced proliferation that 
persists through many measured postnatal ages (Figure 2.6).  Ki-67 is preferentially expressed 
during late G1, S, G2, and M phases of the cell cycle, but not in the resting G0 phase (Scholzen 
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and Gerdes, 2000).  PCNA is an accessory protein for DNA polymerase alpha required for DNA 
synthesis, and is elevated during the G1/S phase of the cell cycle (Kelman, 1997).  Both markers 
indicate that the absence of H19 expression enhances cell proliferation in the developing mouse 
livers.   
Increases in cell proliferation do not directly result in increases in liver mass.  There is a 
discordance with observations in significant liver weight increases and increases in the markers 
indicating cell proliferation in H19 maternal allele knockout mice.  Liver weights are only 
significantly increased immediately in early life and in adult males while increases in 
proliferation are observed throughout most of liver development at postnatal ages.  Interestingly, 
both markers indicate no significant increases in cell proliferation at 15 days after birth despite 
showing significant increases before and after this age in the absence of H19 expression, 
suggesting H19 does not influence proliferation at this specific time of development. 
Loss-of-function of H19 in developing mice induces changes in liver that persist even at 
ages when H19 is not normally expressed (ages 30 and 60 days after birth).  An increase in adult 
male liver weight can be explained by the accumulation of organ mass at earlier ages too subtle 
to have been detected at prior ages.  Increases in proliferation as observed by Ki-67 at ages 30 
and 60 days after birth in H19 maternal allele knockout mice may be the result of more complex 
pathway changes that are initiated at the time of normal H19 expression and persist after H19 is 
no longer expressed.  These late age changes were not observed in the PCNA stain (Figure 2.6 
B). 
We then sought to determine how the loss of H19 expression results in an increase in 
liver mass and an increase in proliferating cells throughout postnatal development by first 
examining IGF signaling.  There is a strong correlation in expression patterns between lncRNAs 
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and protein coding genes within the same loci, suggesting cis regulation with the lncRNA 
potentially influencing its protein coding partner (Peng et al., 2014).  Others have shown that 
regulation is not always the lncRNA acting directly on the protein coding gene, but rather its 
promoter or nearby regulatory regions that influence gene expression of nearby genes (Engreitz 
et al., 2016).  H19 and Igf2 reside next to each other on chromosome 7 in the mouse and have 
similar temporal expression patterns in postnatal liver.  Different H19-null mouse models have 
been used to determine the function of not only H19 RNA, but also regulatory sequences 
surrounding its locus.  Some mouse models have deletions that span into the Imprinting Control 
Region (ICR) between H19 and Igf2 resulting in disruption of imprinting of Igf2, which authors 
have concluded leads to biallelic expression of IGF2 and the overgrowth phenotype (Leighton et 
al., 1995a).  However, our model has only H19 and a portion of its promoter containing an Sp1 
site and TATA box removed, leaving the ICR intact allowing us to study only the effects of H19 
on postnatal liver development (Ripoche et al., 1997).  Our results demonstrate that deletion of 
the ICR, causing bialleleic expression of IGF2, is not needed to induce the overgrowth 
phenotype. 
Our measurements indicate H19 has a minimal effect on IGF2 expression, with 
significant increases in IGF2 expression observed only at 20 days after birth (Figure 2.7 A).  
However, at 5 days after birth, the liver overgrowth phenotype is observed (Figure 2.5 A), and 
cellular proliferation is significantly increased (Figure 2.6) throughout most postnatal ages when 
H19 is not expressed.  This indicates other pathways may be affected by the H19 loss-of-
function. 
The Wnt signaling pathway has been shown to be important in the development of many 
different tissue types and organs.  The canonical intracellular transducer, β-catenin, is activated 
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after the Wnt ligand binds to a Frizzled family receptor.  This activation causes β-catenin 
accumulation in the cytoplasm and its eventual localization into the nucleus where it acts  as a 
coactivator of transcription factors, affecting gene transcription (Rao and Kuhl, 2010).  Cyclin 
D1, a cell cycle inducer important for the G1 to S phase transition, is a target for regulation by β-
catenin (Tetsu and McCormick, 1999) in many different physiological processes including liver 
growth (Monga, 2014).  Wnt signaling has been shown to be inhibited by H19 in fetal liver 
leading to inhibition of cell proliferation (Wang et al., 2016b), and Wnt signaling influences 
proliferation in liver at postnatal ages (Apte et al., 2007).  No significant changes were observed 
at the mRNA level for either β-catenin or a downstream gene target of the pathway important for 
cellular proliferation, cyclin D1, when H19 is not expressed (Figure 2.9).  Protein expression was 
also analyzed for the Wnt ligand and both activated β-catenin and total β-catenin.  Antibody 
detection against Wnt6 was chosen due to Wnt6 being involved in canonical signaling and its 
high expression in developing tissues (Zeng et al., 2007).  No significant changes were observed 
in Wnt6 expression, indicating Wnt signaling was affected only downstream in the pathway.  
Significant differences were discovered at the protein level in early life (age 5 days after birth) 
for active β-catenin, and total β-catenin is also significantly higher at 10 days after birth 
indicating similar results as observed in prior studies examining fetal H19 inhibition of β-catenin 
protein (Wang et al., 2016b).  It is not surprising significant changes were not observed at the 
RNA level for genes within the canonical pathway.  However, mRNA expression for cyclin D1, 
which is a direct target of Wnt signaling at the transcriptional level, was not found to be 
significantly altered. 
H19 encodes a microRNA, miR-675, within its first exon (Cai and Cullen, 2007).  H19 
knockout on the maternal allele abolishes expression of both H19 and miR-675 despite the status 
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of the paternal allele (Figure 2.4).  H19 potentially impacts liver growth and proliferation 
through the action of miR-675.  Prior literature has shown proper processing of miR-675 can 
slow growth in the placenta, and increases of miR-675 downregulate IGF1R, which causes IGF 
signaling to be inhibited (Keniry et al., 2012).  Consistent with our data, removal of H19 
expression only causes a significant increase (Figure 2.7 A) in IGF2 at 20 days after birth despite 
detection of increased liver weights and cell proliferation at earlier ages.  This suggests 
involvement of another regulator.  Although we have found differences in liver development at 
postnatal ages compared to fetal liver development, inhibition of IGF1R by miR-675 may be the 
mechanism by which H19 controls liver growth.  IGF1R expression was examined at both the 
RNA and the protein levels.  No significant differences were found, but a trend of an increase in 
IGF1R expression at the protein level was found for each age measured, suggesting a loss of 
miR-675 expression may be the cause for the overgrowth phenotype and the increase in cell 
proliferation. 
Developmental P450 expression pattern for Cyp3a is not influenced by H19 expression.  
The CYP3A family undergoes a switch in dominant isoforms during postnatal liver 
development.  Early in life, CYP3A16 is the dominant isoform in mice.  The adult CYP3A 
isoform switches to predominantly CYP3A11 around 20 days after birth (Li et al., 2009b).  
Despite this developmental shift pointing to CYP3A potentially being impacted by H19 
expression, no significant differences were observed between wild type mice and mice with the 
maternal H19 allele knocked out (Figures 3.1 A and B). 
However, H19 does affect the expression of P450 enzymes CYP2B10 and CYP2C29 at 
particular points during mouse liver development.  Sex differences in CYP2B10 expression are 
known between wild type males and females.  Wild type adult females are known to display a 
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higher expression level than adult males in mouse liver (Renaud et al., 2011).  Our results also 
point to a sex difference in H19’s role affecting the development of CYP2B10 only significantly 
in male mice and not female mice at 30 days after birth (Figure 3.1 C).  CYP2C29 is not 
normally expressed until the liver begins to mature.  In wild type mice, slight expression is 
observed at 15 days after birth.  In H19 maternal allele knockouts with no H19 expression, the 
expression of CYP2C29 only begins to be detected at 20 days after birth, and at 15 days after 
birth is not expressed and significantly (p<0.05) lower compared to wild type mice (Figure 3.1 
D).  Despite these specific changes, P450s were largely found to be unaffected by H19 
expression indicating H19 may not be important for liver maturation. 
Insignificant changes in expression patterns of albumin and α-fetoprotein, two 
developmentally regulated genes, also indicate H19 may not be important for liver maturation.  
Albumin production is a function and marker of normal mature hepatocytes, but can be detected 
in nascent hepatic cells (Cascio and Zaret, 1991).  Albumin production rises continually 
throughout liver development and is at maximum in adult liver (Jochheim et al., 2004).  Due to 
this expression pattern, we chose the two earliest ages in our study (5 and 10 days after birth) to 
examine changes in albumin production in developing liver in mice with and without H19 
expression.  If H19 affects the maturation of liver, a difference in levels of albumin production 
might be noticed at different developmental ages.  Conversely, α-fetoprotein is a fetal liver gene 
and the major plasma protein present in the fetus.  The RNA expression profile of α-fetoprotein 
in postnatal liver development resembles H19, with highest expression early in life and a 
dramatic decline after birth.  Expression of α-fetoprotein mRNA declines to undetectable levels 
around 14 days after birth in mouse (Pachnis et al., 1984).  Due to this pattern, we chose to 
examine protein expression of α-fetoprotein at ages 15 and 20 days after birth between wild type 
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mice and mice not expressing H19.  Protein expression was still detected at 15 days after birth in 
both groups, but by 20 days after birth, α-fetoprotein protein was not observed for either test 
groups (Figure 3.2 A).  No significant changes were observed in the production of albumin or α-
fetoprotein when H19 is not expressed (Figure 3.2) indicating H19 may not control these 
developmentally regulated genes. 
H19’s role in postnatal liver maturation appears to be consistent with its role in other 
contexts.  H19 is expressed in highly proliferating tissues including fetal and postnatal livers 
(Pachnis et al., 1984), and H19 expression can reemerge in adult liver during hepatocellular 
carcinoma (Kim and Lee, 1997; Matouk et al., 2007), or during regeneration after injury (Pachnis 
et al., 1984; Yamamoto et al., 2004).  Despite its expression in proliferating tissue, our data 
support the hypothesis that normal expression or reemergence of H19 is to limit cellular 
proliferation to control overgrowth.  H19 may be falsely implicated in promoting cell growth if 
basic correlations linking proliferation and H19 expression are made without mechanistic 
examination of H19’s actual molecular role. 
 
4.2 Conclusions 
H19 affects liver growth controlling proliferation through IGF and Wnt signaling, but 
may be inconsequential to liver maturation during postnatal development.  H19’s action is 
potentially through miR-675.  miR-675 has been shown to inhibit IGF1R indicating uninhibited 
IGF signaling may be the cause of the overgrowth phenotype and increases in cell proliferation.  
Despite H19’s regulation of liver growth, evidence suggests H19 may not play a significant role 
in postnatal liver maturation.  Albumin and α-fetoprotein expression patterns were not 
significantly altered, and P450 expression pattern changes were only affected at specific ages. 
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